106 results on '"Mendes-Correa MC"'
Search Results
2. Thyroid Function and CTLA4 Polimorphisms in Chronic Infected Hepatitis C Patients Treated or Not with Interferon alpha and Ribavirine.
- Author
-
Danilovic, DLS, primary, Lima, EU, additional, Mendes-Correa, MC, additional, Chammas, MC, additional, Zambrini, H, additional, Barros, RK, additional, Knobel, M, additional, and Marui, S, additional
- Published
- 2010
- Full Text
- View/download PDF
3. Identification of bacteriophages in the vagina of pregnant women: a descriptive study
- Author
-
Costa, AC, primary, Moron, AF, additional, Forney, LJ, additional, Linhares, IM, additional, Sabino, E, additional, Costa, SF, additional, Mendes‐Correa, MC, additional, and Witkin, SS, additional
- Published
- 2020
- Full Text
- View/download PDF
4. Identification of bacteriophages in the vagina of pregnant women: a descriptive study.
- Author
-
Costa, AC, Moron, AF, Forney, LJ, Linhares, IM, Sabino, E, Costa, SF, Mendes‐Correa, MC, and Witkin, SS
- Subjects
PREGNANT women ,VAGINA ,BACTERIOPHAGES ,PREGNANCY outcomes ,BACTERIAL communities - Abstract
Objective: To determine the presence and identity of extracellular bacteriophage (phage) families, genera and species in the vagina of pregnant women. Design: Descriptive, observational cohort study. Setting: São Paulo, Brazil. Population: Pregnant women at 21–24 weeks' gestation. Methods: Vaginal samples from 107 women whose vaginal microbiome and pregnancy outcomes were previously determined were analysed for phages by metagenomic sequencing. Main outcome measures: Identification of phage families, genera and species. Results: Phages were detected in 96 (89.7%) of the samples. Six different phage families were identified: Siphoviridae in 69.2%, Myoviridae in 49.5%, Microviridae in 37.4%, Podoviridae in 20.6%, Herelleviridae in 10.3% and Inviridae in 1.9% of the women. Four different phage families were present in 14 women (13.1%), three families in 20 women (18.7%), two families in 31 women (29.1%) and one family in 31 women (29.1%). The most common phage species detected were Bacillus phages in 48 (43.6%), Escherichia phages in 45 (40.9%), Staphylococcus phages in 40 (36.4%), Gokushovirus in 33 (30.0%) and Lactobacillus phages in 29 (26.4%) women. In a preliminary exploratory analysis, there were no associations between a particular phage family, the number of phage families present in the vagina or any particular phage species and either gestational age at delivery or the bacterial community state type present in the vagina. Conclusions: Multiple phages are present in the vagina of most mid‐trimester pregnant women. Bacteriophages are present in the vagina of most pregnant women. Bacteriophages are present in the vagina of most pregnant women. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study
- Author
-
Callefi, LA, primary, Villela-Nogueira, CA, additional, Tenore, SB, additional, Carnaúba-Júnior, D, additional, Coelho, HS, additional, Pinto, PT, additional, Nabuco, LC, additional, Pessoa, MG, additional, Ferraz, ML, additional, Ferreira, PR, additional, Martinelli, AL, additional, Chachá, SG, additional, Ferreira, AS, additional, Bisio, AP, additional, Brandão-Mello, CE, additional, Álvares-Da-Silva, MR, additional, Reuter, T, additional, Ivantes, CA, additional, Perez, RM, additional, and Mendes-Correa, MC, additional
- Published
- 2017
- Full Text
- View/download PDF
6. Historical epidemiology of hepatitis C virus (HCV) in selected countries
- Author
-
Bruggmann, P, Berg, T, Øvrehus, ALH, Moreno, C, Brandão Mello, CE, Roudot-Thoraval, F, Marinho, RT, Sherman, M, Ryder, SD, Sperl, J, Akarca, U, Balık, I, Bihl, F, Bilodeau, M, Blasco, AJ, Buti, M, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hézode, C, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marotta, P, Mauss, S, Mendes Correa, MC, Müllhaupt, B, Myers, RP, Negro, F, Nemecek, V, Örmeci, N, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Rosenberg, WM, Sarmento-Castro, R, Sarrazin, C, Semela, D, Shiha, GE, Sievert, W, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Vogel, W, Waked, I, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Van Damme, P, Aleman, S, Hindman, SJ, Bruggmann, P, Berg, T, Øvrehus, ALH, Moreno, C, Brandão Mello, CE, Roudot-Thoraval, F, Marinho, RT, Sherman, M, Ryder, SD, Sperl, J, Akarca, U, Balık, I, Bihl, F, Bilodeau, M, Blasco, AJ, Buti, M, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hézode, C, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marotta, P, Mauss, S, Mendes Correa, MC, Müllhaupt, B, Myers, RP, Negro, F, Nemecek, V, Örmeci, N, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Rosenberg, WM, Sarmento-Castro, R, Sarrazin, C, Semela, D, Shiha, GE, Sievert, W, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Vogel, W, Waked, I, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Van Damme, P, Aleman, S, and Hindman, SJ
- Abstract
Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6,358,000 cases in 2008 and Brazil with 2,106,000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.
- Published
- 2014
7. Strategies to manage hepatitis C virus (HCV) disease burden
- Author
-
Wedemeyer, H, Duberg, AS, Buti, M, Rosenberg, WM, Frankova, S, Esmat, G, Örmeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, El-Sayed, MH, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Guimarães Pessôa, M, Hézode, C, Hindman, SJ, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, RT, Marotta, P, Mauss, S, Mendes Correa, MC, Moreno, C, Müllhaupt, B, Myers, RP, Nemecek, V, Øvrehus, ALH, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, GE, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Vandijck, D, Vogel, W, Waked, I, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W, Gower, E, Wedemeyer, H, Duberg, AS, Buti, M, Rosenberg, WM, Frankova, S, Esmat, G, Örmeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, El-Sayed, MH, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Guimarães Pessôa, M, Hézode, C, Hindman, SJ, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, RT, Marotta, P, Mauss, S, Mendes Correa, MC, Moreno, C, Müllhaupt, B, Myers, RP, Nemecek, V, Øvrehus, ALH, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, GE, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Vandijck, D, Vogel, W, Waked, I, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W, and Gower, E
- Abstract
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
- Published
- 2014
8. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
- Author
-
Razavi, H, Waked, I, Sarrazin, C, Myers, RP, Idilman, R, Calinas, F, Vogel, W, Mendes Correa, MC, Hézode, C, Lázaro, P, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Buti, M, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hindman, SJ, Hofer, H, Husa, P, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Marinho, RT, Marotta, P, Mauss, S, Moreno, C, Murphy, K, Negro, F, Nemecek, V, Örmeci, N, Øvrehus, ALH, Parkes, J, Pasini, K, Peltekian, KM, Ramji, A, Reis, N, Roberts, SK, Rosenberg, WM, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Semela, D, Sherman, M, Shiha, GE, Sievert, W, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Cornberg, M, Müllhaupt, B, Estes, C, Razavi, H, Waked, I, Sarrazin, C, Myers, RP, Idilman, R, Calinas, F, Vogel, W, Mendes Correa, MC, Hézode, C, Lázaro, P, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Buti, M, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hindman, SJ, Hofer, H, Husa, P, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Marinho, RT, Marotta, P, Mauss, S, Moreno, C, Murphy, K, Negro, F, Nemecek, V, Örmeci, N, Øvrehus, ALH, Parkes, J, Pasini, K, Peltekian, KM, Ramji, A, Reis, N, Roberts, SK, Rosenberg, WM, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Semela, D, Sherman, M, Shiha, GE, Sievert, W, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Cornberg, M, Müllhaupt, B, and Estes, C
- Abstract
The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
- Published
- 2014
9. Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil
- Author
-
de Torres Santos AP, Martins Silva VC, Mendes-Corrêa MC, Lemos MF, de Mello Malta F, Santana RAF, Dastoli GTF, de Castro VFD, Pinho JRR, and Moreira RC
- Subjects
hcv ,nonstructural ns5a/ns5b ,resistance ,polymorphism ,ras ,Infectious and parasitic diseases ,RC109-216 - Abstract
Ana Paula de Torres Santos,1,2 Vanessa Cristina Martins Silva,1 Maria Cássia Mendes-Corrêa,3 Marcilio Figueiredo Lemos,1 Fernanda de Mello Malta,4 Rúbia Anita Ferraz Santana,5 Gregório Tadeu Fernando Dastoli,5 Vanessa Fusco Duarte de Castro,5 João Renato Rebello Pinho,2,4,5 Regina Célia Moreira1 1Laboratory of Viral Hepatitis, Virology Center, Instituto Adolfo Lutz, São Paulo, SP, Brazil; 2Divisão de Laboratório Central, Laboratório de Imunologia, Faculdade de Medicina, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brazil; 3LIM-52-Institute of Tropical Medicine, Department of Infectious Diseases, School of Medicine, University of São Paulo, São Paulo, SP, Brazil; 4Laboratory of Tropical Gastroenterology and Hepatology “João de Queiroz and Castorina Bettencourt Alves”‑LIM 07‑Institute of Tropical Medicine Department of Gastroenterology, School of Medicine, University of São Paulo, São Paulo, SP, Brazil; 5Albert Einstein Medicina Diagnóstica, Hospital Israelita Albert Einstein, São Paulo, SP, BrazilCorrespondence: Regina Célia MoreiraInstituto Adolfo Lutz, Centro de Virologia, Av: Dr Arnaldo, 355 Pacaembu, SP, Cep 01246-000, BrazilTel +55 11 30682911Email regina.moreira@ial.sp.gov.brPurpose: Globally, it is estimated that 71 million people are chronically infected with hepatitis C, and 10– 20% of these will develop cirrhosis and hepatocellular carcinoma. The development of new direct-acting antiviral (DAA) drugs has contributed to sustained virological response (SVR), eliminating the infection and achieving cure of chronic hepatitis C. However, treated patients can develop HCV resistance to DAAs, which can contribute to the failure of treatment. Here, we aimed to evaluate the prevalence and specific pattern of NS5A and NS5B resistance-associated substitutions (RAS) in samples from patients chronically infected with HCV genotype 3a at a public health laboratory, Instituto Adolfo Lutz, São Paulo, Brazil.Patients and Methods: Serum samples from the enrolled individuals were submitted to “in-house” polymerase chain reaction amplification of NS5A and NS5B non-structural protein genes, which were then sequenced by Sanger method.Results: A total of 170 and 190 samples were amplified and analyzed for NS5A and NS5B, respectively. For NS5A, 20 (12.0%) samples showed some important RAS; 16 (9.0%) showed some type of substitution and 134 (79.0%) showed no polymorphism. No sample showed any RAS for NS5B.Conclusion: This study found important RAS in samples from naïve chronic HCV patients in some areas from São Paulo. The most prevalent were A62S, A30K, and Y93H, which could indicate an increase in resistance to some DAAs used in HCV treatment.Keywords: HCV, nonstructural NS5A/NS5B, resistance, polymorphism, RAS
- Published
- 2021
10. 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY
- Author
-
Berg, T, Shiffman, ML, Zeuzem, S, Berg, CP, de Figueiredo-Mendes, C, Dore, GJ, Ferraz, ML, Mendes-Correa, MC, Lima, MP, Parise, E, Rios, AMP, Reuter, T, Sanyal, AJ, Shafran, SD, Hohmann, M, Tatsch, F, Cheinquer, H, Berg, T, Shiffman, ML, Zeuzem, S, Berg, CP, de Figueiredo-Mendes, C, Dore, GJ, Ferraz, ML, Mendes-Correa, MC, Lima, MP, Parise, E, Rios, AMP, Reuter, T, Sanyal, AJ, Shafran, SD, Hohmann, M, Tatsch, F, and Cheinquer, H
- Published
- 2013
11. The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study
- Author
-
Cheinquer, H, Shiffman, ML, Zeuzem, S, Berg, CP, Berg, T, Figueiredo-Mendes, CG, Dore, GJ, Ferraz, ML, Mendes-Correa, MC, Lima, MP, Parise, ER, Perez, AM, Reuter, T, Sanyal, AJ, Shafran, SD, Hohmann, M, Tatsch, F, Cheinquer, H, Shiffman, ML, Zeuzem, S, Berg, CP, Berg, T, Figueiredo-Mendes, CG, Dore, GJ, Ferraz, ML, Mendes-Correa, MC, Lima, MP, Parise, ER, Perez, AM, Reuter, T, Sanyal, AJ, Shafran, SD, Hohmann, M, and Tatsch, F
- Published
- 2012
12. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
- Author
-
Mei Hsuan Lee, Maurizia Rossana Brunetto, Stefan Mauss, Sabahattin Kaymakoglu, CE Omuemu, Danjuma Adda, Philip Bruggmann, Beat Müllhaupt, Trân D Quang, Peter Jarcuska, Man-Fung Yuen, George V. Papatheodoridis, Rohani Jahis, Ding-Shinn Chen, Necati Örmeci, Christophe Moreno, Angelos Hatzakis, Antoine Abou Rached, Boris Lukšić, Thomas Berg, Renovat Ntagirabiri, Kathryn Razavi-Shearer, Sarah Blach, Gabriela Rjaskova, Samantha M Brandon, Jen Layden, Ohene Opare-Sem, Maria C Mendes Correa, Stefano Vella, Jan Sperl, Vincent Wai-Sun Wong, Hwai I. Yang, Stephen Oguche, Richard Njouom, Cielo Yaneth Rios, Yee Tak Hui, Behzad Hajarizadeh, Andy I. M. Hoepelman, Javier García-Samaniego, Ammal M. Metwally, Ivane Gamkrelidze, Julia A. Scott, Said A. Al-Busafi, Valentina Liakina, Zaigham Abbas, Olga Sagalova, Rifaat Safadi, Michael Manns, William Sievert, Seyed M Alavian, Kakharman Yesmembetov, Manal H El-Sayed, Juan Francisco Sánchez-Ávila, Wan-Long Chuang, Peter Stärkel, Ziv Ben-Ari, Chris Cunningham, Homie Razavi, Erkin Musabaev, Ulus Salih Akarca, Petr Urbánek, Gamal Shiha, Muhammed Aasim M Yusuf, Nina Weis, Hossein Poustchi, Ilias Gountas, E. A. Croes, Ayman Yosry, Reza Malekzadeh, Kostas Athanasakis, Agustín Albillos, Faleh Z. Al-Faleh, Christoph Sarrazin, Maria Buti, Arif Nawaz, Chung-Lin Yang, Kimberly Murphy, Adriana Vince, Aliya Konysbekova, Soek Siam Tan, Loreta A. Kondili, Mojca Matičič, Karolin Falconer, Hailemichael Desalegn, Alexander Nersesov, Ogu Omede, N. N. Pimenov, Nahum Méndez-Sánchez, Benjamin C Cowie, Helen Nde, Wai-cheung C Lao, Jordan Genov, Imam Waked, Joël Mossong, Ala I. Sharara, Henry Lik-Yuen Chan, Vivek A. Saraswat, Diego Alberto Cuellar, Devin Razavi-Shearer, Abraham O. Malu, Rui Tato Marinho, Huma Qureshi, Markus Cornberg, Faisal M. Sanai, Ching-kong K Loo, David Kershenobich, Pavol Kristian, Paulo R. Ferreira, Mel Krajden, Moon Seok Choi, Junko Tanaka, Faryal Al Lawati, Jonathan Schmelzer, Ann-Sofi Duberg, Jan Gerstoft, Lewis R. Roberts, Francesco Negro, Khalid Al Naamani, Wim Laleman, Solomon Obekpa, Henk W. Reesink, Tesia Shin, Richard Gray, Alnoor Ramji, Fadi H. Mourad, Abdul Rahman Bizri, Joop E. Arends, Shahin Merat, Krzysztof Tomasiewicz, Adkhamjon Mamatkulov, Jerzy Jaroszewicz, Peer Brehm Christensen, Adriaan J. van der Meer, Maheeba Abdulla, Frank Tacke, Cesar Yaghi, Pierre Van Damme, Christopher K Opio, Yasir Waheed, Joseph Woodring, Ponsiano Ocama, Zuridin Nurmatov, Bisi Bright, Van Thi Thuy Nguyen, Perttu Arkkila, Nick Walsh, Catherine A.M. Stedman, Mette Rye Clausen, Vladimir Chulanov, Antonio Craxì, Christophe Hézode, Abdulrahman Aljumah, Jeffrey V. Lazarus, Fuad Hasan, Sarah Robbins, Sona Frankova, Adrian Goldis, Rong-Nan Chien, Chris Estes, Stephen D. Ryder, Nguyen Thu Anh, Abate Bane, Muhammad S. Memon, Ken Pasini, Ivan Schréter, Sameer Alawadhi, Stuart K. Roberts, Steve S Egeonu, Anil C. Anand, Riina Salupere, Massimo Colombo, Giovanni Battista Gaeta, Maria Lucia Gomes Ferraz, Rosmawati Mohamed, Sylvia Drazilova, Hans Van Vlierberghe, Soo Aleman, Naveed Z. Janjua, Irena Hrstić, Manik Sharma, Carlos E Brandão Mello, Mario G. Pessoa, Berhane Redae, Mindie H. Nguyen, Petr Husa, Vana Sypsa, Samir Shah, Jacques E Mokhbat, Robert Flisiak, Carole Seguin-Devaux, Asad Chaudhry, Inka Aho, Sayed Himatt, Hamad I. Al-Ashgar, Young-Suk Lim, Stefan Zeuzem, University of Zurich, Polaris Observatory Collaborators, Polaris Observ Collaborators, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Experimental Immunology, Gastroenterology & Hepatology, Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z, Abdulla M, Abou Rached A, Adda D, Aho I, Akarca U, Hasan F, Al Lawati F, Al Naamani K, Al-Ashgar HI, Alavian SM, Alawadhi S, Albillos A, Al-Busafi SA, Aleman S, Alfaleh FZ, Aljumah AA, Anand AC, Anh NT, Arends JE, Arkkila P, Athanasakis K, Bane A, Ben-Ari Z, Berg T, Bizri AR, Blach S, Brandão Mello CE, Brandon SM, Bright B, Bruggmann P, Brunetto M, Buti M, Chan HLY, Chaudhry A, Chien RN, Choi MS, Christensen PB, Chuang WL, Chulanov V, Clausen MR, Colombo M, Cornberg M, Cowie B, Craxi A, Croes EA, Cuellar DA, Cunningham C, Desalegn H, Drazilova S, Duberg AS, Egeonu SS, El-Sayed MH, Estes C, Falconer K, Ferraz MLG, Ferreira PR, Flisiak R, Frankova S, Gaeta GB, García-Samaniego J, Genov J, Gerstoft J, Goldis A, Gountas I, Gray R, Guimarães Pessôa M, Hajarizadeh B, Hatzakis A, Hézode C, Himatt SM, Hoepelman A, Hrstic I, Hui YT, Husa P, Jahis R, Janjua NZ, Jarčuška P, Jaroszewicz J, Kaymakoglu S, Kershenobich D, Kondili LA, Konysbekova A, Krajden M, Kristian P, Laleman W, Lao WC, Layden J, Lazarus JV, Lee MH, Liakina V, Lim YS, Loo CK, Lukšić B, Malekzadeh R, Malu AO, Mamatkulov A, Manns M, Marinho RT, Maticic M, Mauss S, Memon MS, Mendes Correa MC, Mendez-Sanchez N, Merat S, Metwally AM, Mohamed R, Mokhbat JE, Moreno C, Mossong J, Mourad FH, Müllhaupt B, Murphy K, Musabaev E, Nawaz A, Nde HM, Negro F, Nersesov A, Nguyen VTT, Njouom R, Ntagirabiri R, Nurmatov Z, Obekpa S, Ocama P, Oguche S, Omede O, Omuemu C, Opare-Sem O, Opio CK, Örmeci N, Papatheodoridis G, Pasini K, Pimenov N, Poustchi H, Quang TD, Qureshi H, Ramji A, Razavi-Shearer K, Redae B, Reesink HW, Rios CY, Rjaskova G, Robbins S, Roberts LR, Roberts SK, Ryder SD, Safadi R, Sagalova O, Salupere R, Sanai FM, Sanchez-Avila JF, Saraswat V, Sarrazin C, Schmelzer JD, Schréter I, Scott J, Seguin-Devaux C, Shah SR, Sharara AI, Sharma M, Shiha GE, Shin T, Sievert W, Sperl J, Stärkel P, Stedman C, Sypsa V, Tacke F, Tan SS, Tanaka J, Tomasiewicz K, Urbanek P, van der Meer AJ, Van Vlierberghe H, Vella S, Vince A, Waheed Y, Waked I, Walsh N, Weis N, Wong VW, Woodring J, Yaghi C, Yang HI, Yang CL, Yesmembetov K, Yosry A, Yuen MF, Yusuf MAM, Zeuzem S, Razavi H., Negro, Francesco, Razavi-Shearer, Devin, Gamkrelidze, Ivane, Nguyen, Mindie H, Chen, Ding-Shinn, Van Damme, Pierre, Abbas, Zaigham, Abdulla, Maheeba, Abou Rached, Antoine, Adda, Danjuma, Aho, Inka, Akarca, Ulu, Hasan, Fuad, Al Lawati, Faryal, Al Naamani, Khalid, Al-Ashgar, Hamad Ibrahim, Alavian, Seyed M, Alawadhi, Sameer, Albillos, Agustin, Al-Busafi, Said A, Aleman, Soo, Alfaleh, Faleh Z, Aljumah, Abdulrahman A, Anand, Anil C, Anh, Nguyen Thu, Arends, Joop E, Arkkila, Perttu, Athanasakis, Kosta, Bane, Abate, Ben-Ari, Ziv, Berg, Thoma, Bizri, Abdul R, Blach, Sarah, Brandão Mello, Carlos E, Brandon, Samantha M, Bright, Bisi, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Chan, Henry L Y, Chaudhry, Asad, Chien, Rong-Nan, Choi, Moon S, Christensen, Peer B, Chuang, Wan-Long, Chulanov, Vladimir, Clausen, Mette R, Colombo, Massimo, Cornberg, Marku, Cowie, Benjamin, Craxi, Antonio, Croes, Esther A, Cuellar, Diego Alberto, Cunningham, Chri, Desalegn, Hailemichael, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve S, El-Sayed, Manal H, Estes, Chri, Falconer, Karolin, Ferraz, Maria L G, Ferreira, Paulo R, Flisiak, Robert, Frankova, Sona, Gaeta, Giovanni B, García-Samaniego, Javier, Genov, Jordan, Gerstoft, Jan, Goldis, Adrian, Gountas, Ilia, Gray, Richard, Guimarães Pessôa, Mário, Hajarizadeh, Behzad, Hatzakis, Angelo, Hézode, Christophe, Himatt, Sayed M, Hoepelman, Andy, Hrstic, Irena, Hui, Yee-Tak T, Husa, Petr, Jahis, Rohani, Janjua, Naveed Z, Jarčuška, Peter, Jaroszewicz, Jerzy, Kaymakoglu, Sabahattin, Kershenobich, David, Kondili, Loreta A, Konysbekova, Aliya, Krajden, Mel, Kristian, Pavol, Laleman, Wim, Lao, Wai-cheung C, Layden, Jen, Lazarus, Jeffrey V, Lee, Mei-Hsuan, Liakina, Valentina, Lim, Young-Suk S, Loo, Ching-kong K, Lukšić, Bori, Malekzadeh, Reza, Malu, Abraham O, Mamatkulov, Adkhamjon, Manns, Michael, Marinho, Rui T, Maticic, Mojca, Mauss, Stefan, Memon, Muhammad S, Mendes Correa, Maria C, Mendez-Sanchez, Nahum, Merat, Shahin, Metwally, Ammal M, Mohamed, Rosmawati, Mokhbat, Jacques E, Moreno, Christophe, Mossong, Joel, Mourad, Fadi H, Müllhaupt, Beat, Murphy, Kimberly, Musabaev, Erkin, Nawaz, Arif, Nde, Helen M, Nersesov, Alexander, Nguyen, Van Thi Thuy, Njouom, Richard, Ntagirabiri, Renovat, Nurmatov, Zuridin, Obekpa, Solomon, Ocama, Ponsiano, Oguche, Stephen, Omede, Ogu, Omuemu, Casimir, Opare-Sem, Ohene, Opio, Christopher K, Örmeci, Necati, Papatheodoridis, George, Pasini, Ken, Pimenov, Nikolay, Poustchi, Hossein, Quang, Trân D, Qureshi, Huma, Ramji, Alnoor, Razavi-Shearer, Kathryn, Redae, Berhane, Reesink, Henk W, Rios, Cielo Yaneth, Rjaskova, Gabriela, Robbins, Sarah, Roberts, Lewis R, Roberts, Stuart K, Ryder, Stephen D, Safadi, Rifaat, Sagalova, Olga, Salupere, Riina, Sanai, Faisal M, Sanchez-Avila, Juan F, Saraswat, Vivek, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Scott, Julia, Seguin-Devaux, Carole, Shah, Samir R, Sharara, Ala I, Sharma, Manik, Shiha, Gamal E, Shin, Tesia, Sievert, William, Sperl, Jan, Stärkel, Peter, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek S, Tanaka, Junko, Tomasiewicz, Krzysztof, Urbanek, Petr, van der Meer, Adriaan J, Van Vlierberghe, Han, Vella, Stefano, Vince, Adriana, Waheed, Yasir, Waked, Imam, Walsh, Nichola, Weis, Nina, Wong, Vincent W, Woodring, Joseph, Yaghi, Cesar, Yang, Hwai-I, Yang, Chung-Lin, Yesmembetov, Kakharman, Yosry, Ayman, Yuen, Man-Fung, Yusuf, Muhammed Aasim M, Zeuzem, Stefan, and Razavi, Homie
- Subjects
0301 basic medicine ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences ,HBsAg ,Pediatrics ,Delphi Technique ,Infectious Disease Transmission ,CHRONIC HBV INFECTION ,NATURAL-HISTORY ,FOLLOW-UP ,HBSAG ,CARRIERS ,AGE ,COUNTRIES ,DISEASE ,ANTIGEN ,COHORT ,ddc:616.07 ,Global Health ,medicine.disease_cause ,0302 clinical medicine ,Prevalence ,HBV ,Child ,ddc:616 ,Antiviral Agents/therapeutic use ,education.field_of_study ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti ,Chronic/drug therapy/epidemiology/prevention & control/transmission ,Gastroenterology ,Hepatitis B Surface Antigens/blood ,Hepatitis B ,10219 Clinic for Gastroenterology and Hepatology ,Child, Preschool ,030211 gastroenterology & hepatology ,Viral hepatitis ,Viral load ,Adult ,medicine.medical_specialty ,Hepatitis B vaccine ,Population ,610 Medicine & health ,Antiviral Agents ,Mass Vaccination ,Hepatology ,03 medical and health sciences ,Hepatitis B, Chronic ,SDG 3 - Good Health and Well-being ,medicine ,Humans ,2715 Gastroenterology ,Preschool ,education ,Disease burden ,Hepatitis B virus ,Hepatitis B Surface Antigens ,business.industry ,Viral Vaccines ,medicine.disease ,Infectious Disease Transmission, Vertical ,Vertical/prevention & control ,030104 developmental biology ,2721 Hepatology ,Human medicine ,business - Abstract
PubMed: 29599078, 2-s2.0-85044540918, Background: The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment. Methods: In this modelling study, we used a Delphi process that included a literature review in PubMed and Embase, followed by interviews with experts, to quantify the historical epidemiology of HBV infection. We then used a dynamic HBV transmission and progression model to estimate the country-level and regional-level prevalence of HBsAg in 2016 and the effect of prophylaxis and treatment on disease burden. Findings: We developed models for 120 countries, 78 of which were populated with data approved by experts. Using these models, we estimated that the global prevalence of HBsAg in 2016 was 3·9% (95% uncertainty interval [UI] 3·4–4·6), corresponding to 291 992 000 (251 513 000–341 114 000) infections. Of these infections, around 29 million (10%) were diagnosed, and only 4·8 million (5%) of 94 million individuals eligible for treatment actually received antiviral therapy. Around 1·8 (1·6–2·2) million infections were in children aged 5 years, with a prevalence of 1·4% (1·2–1·6). We estimated that 87% of infants had received the three-dose HBV vaccination in the first year of life, 46% had received timely birth-dose vaccination, and 13% had received hepatitis B immunoglobulin along with the full vaccination regimen. Less than 1% of mothers with a high viral load had received antiviral therapy to reduce mother-to-child transmission. Interpretation: Our estimate of HBV prevalence in 2016 differs from previous studies, potentially because we took into account the effect of infant prophylaxis and early childhood vaccination, as well as changing prevalence over time. Although some regions are well on their way to meeting prophylaxis and prevalence targets, all regions must substantially scale-up access to diagnosis and treatment to meet the global targets. Funding: John C Martin Foundation. © 2018 Elsevier Ltd, H28-kansei-ippan-001 National Academy of Sciences, NAS Novartis Roche World Health Organization, WHO Gilead Sciences Alnylam Pharmaceuticals AbbVie Meso Scale Diagnostics, MSD British Microcirculation Society, BMS Japan Society for the Promotion of Science, JSPS: 17H03589 Ministry of Health, Labour and Welfare, MHLW Vetenskapsrådet, VR Siemens Universiteit Antwerpen OLL-683801, DR-S, IGa, SB, SMB, CE, KM, HMN, KP, KR-S, SR, JDS, and HR report grants from John C Martin Foundation, during the conduct of the study, and grants from Gilead Sciences, AbbVie, WHO, National Academy of Sciences, Intercept Pharmaceuticals, and Boehringer Ingelheim, outside the submitted work. MHN reports grants and personal fees from Bristol-Myers Squibb (BMS), Gilead Sciences, and Janssen, and personal fees from Novartis, Anylam, and Dynavax, outside the submitted work. PVD acts as chief and principal investigator for vaccine trials done on behalf of the University of Antwerp, Belgium, for which the University obtains research grants from vaccine manufacturers; speaker's fees for presentations on vaccines are paid directly to an educational fund held by the University of Antwerp, and PVD receives no personal remuneration for this work. ACA reports personal fees from Mylan Pharmaceuticals, outside the submitted work. JEA reports fees paid to his hospital for participation on the advisory boards of Gilead Sciences, ViiV Healthcare, BMS, Janssen, and AbbVie, and grants from BMS, Merck Sharp & Dohme (MSD), AbbVie, and ViiV Healthcare, outside the submitted work. TB reports grants, personal fees, and non-financial support from AbbVie and Gilead Sciences; grants and personal fees from BMS, Janssen, Roche, MSD, and Sequana Medical; and personal fees from Bayer, Vertex, Tibotec, Intercept, Sirtex, and Alexion, outside the submitted work. PB reports grants and personal fees from AbbVie, Gilead Sciences, and MSD, outside the submitted work. MBr reports personal fees from BMS, Gilead Sciences, and Janssen, and grants from BMS, outside the submitted work. HLYC reports personal fees from Gilead Sciences, BMS, AbbVie, Roche, MedImmune, and Intellia, outside the submitted work. PBC reports grants from AbbVie, Gilead Sciences, and MSD, outside the submitted work. VC reports personal fees from AbbVie, BMS, Gilead Sciences, and MSD, and grants from BMS, outside the submitted work. MCor reports personal fees from AbbVie, BMS, Boehringer Ingelheim, Biogen Idec, Falk Foundation, Gilead Sciences, Janssen, MSD, Roche Diagnostics, Roche Pharma, and Siemens, outside the submitted work. SD and PJ report personal fees and non-financial support from AbbVie and Gilead Sciences, and personal fees from MSD, outside the submitted work. MHE-S is an advisory board member for Perspectum Diagnostics, and reports grants and non-financial support from Gilead Sciences, and non-financial support from AbbVie and Quadri Pharma, outside the submitted work. RF reports grants, personal fees, and non-financial support from Roche and Gilead Sciences, and personal fees and non-financial support from BMS, outside the submitted work. GBG reports grants and personal fees from Gilead Sciences, outside the submitted work. JG-S reports grants and personal fees from Gilead Sciences, and personal fees from MSD, Abbvie, Janssen, and BMS, outside the submitted work. JGer reports grants and personal fees from AbbVie, Gilead Sciences, Janssen, MSD, BMS, and ViiV Healthcare, outside the submitted work. RG reports grants from New South Wales Ministry of Health and provided project advice regarding viral hepatitis treatment to Gilead Sciences, outside the submitted work. AHa reports unrestricted grants from AbbVie, MSD, Gilead Sciences, BMS, and Novartis, and non-financial support from Gilead Sciences, outside the submitted work; he was also on advisory boards for AbbVie, Gilead Sciences, and BMS. CH reports personal fees from AbbVie, BMS, Gilead Sciences, Janssen, and MSD, outside the submitted work. JJ reports personal fees and non-financial support from Gilead Sciences and AbbVie, and personal fees from Roche and BMS, outside the submitted work. MK reports grants from Roche, Siemens, Hologic, and Boerhinger Ingleheim, outside the submitted work. JVL reports grants and personal fees from Gilead Sciences and personal fees from Cepheid, outside the submitted work. MMan reports personal fees from Roche, BMS, GlaxoSmithKline, Aevi Genomic Medicine, ENYO Pharma, and CureVac, and grants and personal fees from Gilead Sciences and Novartis, outside the submitted work. SMau reports personal fees and non-financial support from Gilead Sciences and BMS, outside the submitted work. CM reports grants and personal fees from AbbVie, Gilead Sciences, and BMS; personal fees from MSD; and grants from Roche, outside the submitted work. BM reports grants and personal fees from Gilead Sciences and personal fees from AbbVie, MSD, BMS, Bayer, Intercept, and Sigma-Tau, during the conduct of the study. FN reports personal fees and non-financial support from Gilead Sciences, during the conduct of the study. AR reports grants and personal fees from AbbVie, Gilead, and MSD, and personal fees form BMS, Celgene, Janssen, Intercept, and Lupin, outside the submitted work. HWR reports grants and personal fees from AbbVie, BMS, Boehringer Ingelheim, ENYO Pharma, Gilead Sciences, Janssen, MSD, PRA Health Sciences, Regulus, and Roche; personal fees from Alnylam and R-Pharm; and grants from Replicor, outside the submitted work. LRR reports grants from the Center for Clinical and Translational Science and the Swedish Research Council (Ghana), during the conduct of the study. LRR also reports grants from Gilead Sciences, BTG, Ariad, and Wako, outside the submitted work, and was a consultant and advisory board member for Wako, Medscape, Axis, OncLive, Bayer, Tavec, and Grail. SDR has served as an advisory board member and speaker for Gilead Sciences, AbbVie, and MSD. OS has served as a consultant and on advisory boards for MSD; received research grants from AbbVie, BMS, MSD, Boehringer Ingelheim, R-Pharm, and Hepatera; and served as a speaker for Abbott, AbbVie, BMS, Gilead Sciences, Janssen, MSD, and R-Pharm. JFS-A reports personal fees from AbbVie and grants from Gilead Sciences and Janssen, outside the submitted work. CSa reports personal fees from Gilead Sciences and BMS, outside the submitted work. PS reports grants and personal fees from Gilead Sciences, AbbVie, and BMS, and personal fees from Intercept, outside the submitted work. CSt has consulted with and served on advisory boards for Gilead Sciences, AbbVie, and MSD. VSy reports grants and personal fees from Gilead Sciences, personal fees and non-financial support from AbbVie, and personal fees from Janssen, outside the submitted work. KT reports grants and personal fees from AbbVie, Gilead Sciences, and BMS; personal fees from MSD and Alfa Wasserman; and grants from Janssen, outside the submitted work. AJvdM reports grants and personal fees from Gilead Sciences and personal fees from AbbVie, outside the submitted work. IW reports personal fees from AbbVie, Gilead Sciences, Janssen, Marcyrl, Mylan, Onxio, and Pharco, outside the submitted work. NW reports personal fees paid to her department from AbbVie, BMS, Gilead Sciences, and MSD, outside the submitted work. VWW reports personal fees from Gilead Sciences, BMS, and MSD, outside the submitted work. M-FY was a speaker or advisory board member for AbbVie, BMS, Gilead Sciences, Roche, GlaxoSmithKline, Fujirebio, Biocartis, and MSD, outside the submitted work. SZ reports consultancy and lecture fees from AbbVie, Gilead Sciences, and MSD, and consultancy fees from Intercept, outside the submitted work. All other authors declare no competing interests., This study was funded by the John C Martin Foundation through the Polaris Observatory. We thank the Research on Hepatitis group (H28-kansei-ippan-001 and H25-kanen-ippan-010; led by JT), funded by the Ministry of Health, Labour and Welfare of Japan, for their provision of country-level data for Japan, and Örebro County Council for providing ALF grants (OLL-683801) to A-SD, which allowed collection of country-level data for Sweden.
- Published
- 2018
13. Corrigendum to: Novel members of the order Picornavirales identified in freshwater from Guarapiranga reservoir in São Paulo (infection, Genetics and Evolution Volume 124, October 2024, 105668).
- Author
-
do Socorro Foro Ramos E, Barbosa MRF, Villanova F, Silva RLO, Garcia SC, Mendes-Correa MC, Pandey RP, Luchs A, Sato MIZ, da Costa AC, and Leal E
- Published
- 2024
- Full Text
- View/download PDF
14. Novel members of the order Picornavirales identified in freshwater from Guarapiranga reservoir in São Paulo.
- Author
-
do Socorro Foro Ramos E, Barbosa MRF, Villanova F, Silva RLO, Garcia SC, Mendes-Correa MC, Pandey RP, Luchs A, Sato MIZ, da Costa AC, and Leal E
- Subjects
- Brazil, Metagenomics methods, Genome, Viral, Picornaviridae genetics, Picornaviridae classification, Picornaviridae isolation & purification, Fresh Water virology, Phylogeny
- Abstract
The global challenge of water resource availability is exacerbated by anthropogenic influences that promote the emergence of pollutants. Among these pollutants are microbiological agents, including viruses, which are ubiquitous in the biosphere and play a pivotal role in both ecological balance and the occurrence of diseases in animals and plants. Consequently, monitoring viruses in water sources becomes indispensable for the establishment of effective prevention, promotion, and control strategies. Within this context, the study focuses on the identification of novel viruses belonging to the Picornavirales order in freshwater from the Guarapiranga Reservoir in the state of São Paulo, Brazil. The samples were subjected to viral metagenomics. Our analysis led to the characterization of four distinct sequences (GinkV-05, AquaV_10, MarV_14, and MarV_64), which exhibited significant divergence compared to other members of the Picornavirales order. This remarkable diversity prompted the identification of a potential new genus within the Marnaviridae family, tentatively named Ginkgonavirus. Additionally, we characterized four sequences in a very distinct clade and propose the recognition of a novel family (named Aquaviridae) within the Picornavirales order. Our findings contribute valuable insights into the previously uncharted diversity of Picornavirales present in water sources, shedding light on an important facet of viral ecology and evolution in aquatic environments., Competing Interests: Declaration of competing interest The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
15. First Detection and Characterization of Smacovirus in the Human Vagina in Two Sequential Samples over a Twelve-Day Interval.
- Author
-
da Costa AC, Tozetto-Mendoza TR, Foro Ramos EDS, Bortoletto P, Ferreira NE, Honorato L, Garcia Barbosa EM, Paião HGO, de Souza AF, Linhares IM, Spandorfer SD, Leal E, Mendes-Correa MC, and Witkin SS
- Subjects
- Humans, Female, Adult, Metagenomics methods, DNA, Viral genetics, DNA Viruses genetics, DNA Viruses isolation & purification, DNA Viruses classification, New York City, Young Adult, Middle Aged, Vagina virology, Phylogeny, Genome, Viral
- Abstract
Background: Smacovirus is a CRESS-DNA virus identified almost exclusively in transient fecal samples from various vertebrate species., Objective: We evaluated human vaginal samples for the presence and maintenance of Smacovirus ., Methods: Viral metagenomics analysis was performed on vaginal samples collected from 28 apparently healthy women in New York City, USA. Twenty-one of the women provided duplicate samples over a 12-21-day interval., Results: Phylogenetic analysis identified two samples from the same individual, collected over a twelve-day interval, that were positive for the complete Smacovirus genome. All detected sequence contigs belonged to a single variant of CRESS-DNA., Conclusions: The continuous presence of Smacovirus in the human vagina over a twelve-day period was identified.
- Published
- 2024
- Full Text
- View/download PDF
16. Characterization of multiple human papillomavirus types in the human vagina following ovarian hormonal stimulation.
- Author
-
Foro Ramos EDS, da Silva Couto R, Tozetto-Mendoza TR, Bortoletto P, Barbosa EMG, Ferreira NE, Linhares IM, Spandorfer SD, da Costa AC, Leal E, Mendes-Correa MC, and Witkin SS
- Subjects
- Humans, Female, Adult, DNA, Viral genetics, Sequence Analysis, DNA, Young Adult, Metagenomics, Genotype, Human Papillomavirus Viruses, Vagina virology, Papillomavirus Infections virology, Phylogeny, Papillomaviridae genetics, Papillomaviridae classification, Papillomaviridae isolation & purification, Ovulation Induction
- Abstract
The objective of study was to characterize HPV in vaginal samples from women being seen at the Center for Reproductive Medicine and Infertility at Weill Cornell Medicine before and following ovarian stimulation. A total of 29 women made samples available for analysis by viral metagenomics. Eighteen women were HPV-positive, six (33.3%) at their initial visit and 15 (83.3%) following hormone stimulation (p = 0.0059). Pairwise comparison of nucleotide sequences and phylogenetic analysis showed the classification sequences into two genera: Alphapapillomavirus and Gammapapillomavirus. Sequences were from 8 HPV types: HPV 51 (n = 2), HPV 68 (n = 1), HPV 83 (n = 9), HPV 84 (n = 2), HPV 121 (n = 6), HPV 175 (n = 1) and HPV 190 (n = 1). Additionally, C16b and C30 likely represent new types. In summary, multiple HPV types are present in the vagina of reproductive age women and are induced by hormone used to stimulate ovulation., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Ocular manifestations of Monkeypox virus (MPXV) infection with viral persistence in ocular samples: A case series.
- Author
-
Finamor LPS, Mendes-Correa MC, Rinkevicius M, Macedo G, Sabino EC, Villas-Boas LS, de Paula AV, de Araujo-Heliodoro RH, da Costa AC, Witkin SS, Santos KLC, Palmeira C, Andrade G, Lucena M, de Freitas Santoro D, da Silva LMP, and Muccioli C
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Uveitis virology, Uveitis diagnosis, Uveitis drug therapy, Keratitis virology, Keratitis diagnosis, Keratitis drug therapy, Eye Infections, Viral virology, Eye Infections, Viral diagnosis, Eye Infections, Viral drug therapy, Eye virology, Antiviral Agents therapeutic use, Mpox (monkeypox) virology, Mpox (monkeypox) diagnosis, Monkeypox virus genetics, Monkeypox virus isolation & purification
- Abstract
Objective: We describe the clinical presentation and ocular viral dynamics in patients with Monkeypox virus-related ophthalmic disease (MPXROD)., Methods: In this case series, we investigated five consecutive patients with confirmed mpox, diagnosed through a positive Monkeypox virus (MPXV) Polymerase Chain Reaction (PCR) test and presenting with ocular symptoms. They were referred from the Reference Center for Sexually Transmitted Infections in São Paulo (CRT) to the Uveitis Sector at the Federal University of São Paulo, between August and December 2022. We performed PCR testing on ocular samples and culture supernatants for MPXV in all patients. Viral sequencing was conducted in one of the cases., Results: Replicating MPXV was identified in at least one ocular sample of all patients, between day 31 and day 145 after the onset of skin lesions. All patients presented with keratitis, 3 with uveitis (60%) and two exhibited hypopyon (40%). The onset of ocular symptoms occurred at a mean of 21.2 days after the appearance of the first skin lesion and persisted, on average, for 61,.6 days, with a worsening trend observed until the initiation of tecovirimat treatment. Tecovirimat treatment was administered to all patients, with initiation occurring between 31 and 145 days after the onset of skin lesions. MPXV genome sequencing of an isolate from one patient classified it as belonging to lineage B1 in clade IIb., Conclusion: This study reveals a late onset and persistence of sight threatening ocular disease, along with potential viral infectivity even after systemic resolution in mpox cases. These findings highlight the risk of ongoing transmission from individuals with prolonged ocular manifestations, particularly through ocular discharge., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Progressive multifocal leukoencephalopathy and spectrum of predisposing conditions: a 20-year retrospective cohort study in a tertiary center in São Paulo, Brazil.
- Author
-
Mari JF, de Miranda ÉJFP, Mendes-Correa MC, Chow FC, and Vidal JE
- Abstract
Background: Epidemiological studies on predisposing conditions and outcomes of progressive multifocal leukoencephalopathy (PML) cases have been carried out exclusively in high-income countries. We aim to report and compare the main characteristics and outcomes of patients with PML and several underlying diseases in a referral center in a middle-income country., Methods: We performed a retrospective cohort study of PML cases admitted to a tertiary care hospital in São Paulo, Brazil during 2000-2022. Demographic and PML-specific variables were recorded. One-year case-fatality rate and factors associated with death were identified using a multivariate Cox proportional hazards regression model., Results: Ninety-nine patients with PML were included. HIV infection (84.8%) and malignancy (14.1%) were the most prevalent underlying conditions. Other predisposing diseases were autoimmune/inflammatory diseases (5.1%) and solid organ transplantation (1.0%). One (1.0%) patient had liver cirrhosis and another (1.0%) patient was previously healthy. Focal motor deficits (64.2%) and gait instability (55.1%) were the most common signs. The one-year case-fatality rate was 52.5% (95% CI 42.2-62.7). The one-year case-fatality rate (95% CI) in patients with or without malignancy (85.7%, 95% CI 57.2-98.2% and 47.1%, 95% CI 36.1-58.2%, respectively) were statistically different (P = 0.009). Crude and adjusted Cox regression models identified malignancy as independently associated with death (adjusted HR = 3.92, 95% CI 1.76-8.73, P = 0.001)., Conclusions: HIV/AIDS was the predisposing condition in 84.8% of PML cases. The one-year case-fatality rate was 52.5% and having a malignancy was independently associated with death. This study reports emerging data on the epidemiology and outcome of PML in a middle-income country., (© 2024. Fondazione Società Italiana di Neurologia.)
- Published
- 2024
- Full Text
- View/download PDF
19. Characterization of CRESS-DNA viruses in human vaginal secretions: An exploratory metagenomic investigation.
- Author
-
Ramos EDSF, Tozetto-Mendoza TR, Bortoletto P, Ferreira NE, Honorato L, Barbosa EMG, Luchs A, Linhares IM, Spandorfer SD, Leal E, da Costa AC, Witkin SS, and Mendes-Correa MC
- Subjects
- Humans, Female, Adult, DNA, Viral genetics, New York City, Sequence Analysis, DNA, Genetic Variation, Phylogeny, Metagenomics, Vagina virology, Genome, Viral genetics, DNA Viruses genetics, DNA Viruses classification, DNA Viruses isolation & purification
- Abstract
The Phylum Cressdnaviricota consists of a large number of circular Rep-encoding single-stranded (CRESS)-DNA viruses. Recently, metagenomic analyzes revealed their ubiquitous distribution in a diverse range of eukaryotes. Data relating to CRESS-DNA viruses in humans remains scarce. Our study investigated the presence and genetic diversity of CRESS-DNA viruses in human vaginal secretions. Vaginal swabs were collected from 28 women between 29 and 43 years old attending a fertility clinic in New York City. An exploratory metagenomic analysis was performed and detection of CRESS-DNA viruses was confirmed through analysis of near full-length sequences of the viral isolates. A phylogenetic tree was based on the REP open reading frame sequences of the CRESS-DNA virus genome. Eleven nearly complete CRESS-DNA viral genomes were identified in 16 (57.1%) women. There were no associations between the presence of these viruses and any demographic or clinical parameters. Phylogenetic analysis indicated that one of the sequences belonged to the genus Gemycircularvirus within the Genomoviridae family, while ten sequences represented previously unclassified species of CRESS-DNA viruses. Novel species of CRESS-DNA viruses are present in the vaginal tract of adult women. Although they be transient commensal agents, the potential clinical implications for their presence at this site cannot be dismissed., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
20. Analysis of chlorhexidine, antibiotics and bacterial community composition in water environments from Brazil, Cameroon and Madagascar during the COVID-19 pandemic.
- Author
-
Scaccia N, da Silva Fonseca JV, Megueya AL, de Aragão GL, Rasolofoarison T, de Paula AV, de Vinci Kanda Kupa L, Tchatchueng J, Makuetche K, Rasolojaona TZ, Rasamoelina T, Razzolini MTP, Duarte NJC, Mendes-Correa MC, Samison LH, Guimaraes T, Sabino EC, Komurian-Pradel F, Nzouankeu A, and Costa SF
- Subjects
- Brazil, Cameroon, Madagascar, Water Pollutants, Chemical analysis, Bacteria, Environmental Monitoring, SARS-CoV-2, Water Microbiology, COVID-19 epidemiology, Anti-Bacterial Agents analysis, Chlorhexidine, Wastewater microbiology, Wastewater virology
- Abstract
The widespread of chlorhexidine and antibiotics in the water bodies, which grew during the global COVID-19 pandemic, can increase the dispersion of antibiotic resistance. We assessed the occurrence of these pharmaceutical compounds as well as SARS-CoV-2 and analysed the bacterial community structure of hospital and urban wastewaters from Brazil, Cameroon, and Madagascar. Water and wastewater samples (n = 59) were collected between January-June 2022. Chlorhexidine, azithromycin, levofloxacin, ceftriaxone, gentamicin and meropenem were screened by Ultra-High-Performance Liquid Chromatography coupled with mass spectrometer. SARS-CoV-2 was detected based on the nucleocapsid gene (in Cameroon and Madagascar), and envelope and spike protein-encoding genes (in Brazil). The total community-DNA was extracted and used for bacterial community analysis based on the 16S rRNA gene. To unravel likely interaction between pharmaceutical compounds and/or SARS-CoV-2 with the water bacterial community, multivariate statistics were performed. Chlorhexidine was found in hospital wastewater effluent from Brazil with a maximum concentration value of 89.28 μg/L. Additionally, antibiotic residues such as azithromycin and levofloxacin were also present at concentrations between 0.32-7.37 μg/L and 0.11-118.91 μg/L, respectively. In Cameroon, azithromycin was the most found antibiotic present at concentrations from 1.14 to 1.21 μg/L. In Madagascar instead, ceftriaxone (0.68-11.53 μg/L) and levofloxacin (0.15-0.30 μg/L) were commonly found. The bacterial phyla statistically significant different (P < 0,05) among participating countries were Proteobacteria, Patescibacteria and Dependentiae which were mainly abundant in waters sampled in Africa and, other phyla such as Firmicutes, Campylobacterota and Fusobacteriota were more abundant in Brazil. The phylum Caldisericota was only found in raw hospital wastewater samples from Madagascar. The canonical correspondence analysis results suggest significant correlation of azithromycin, meropenem and levofloxacin with bacteria families such as Enterococcaceae, Flavobacteriaceae, Deinococcaceae, Thermacetogeniaceae and Desulfomonilaceae, Spirochaetaceae, Methanosaetaceae, Synergistaceae, respectively. Water samples were also positive for SARS-CoV-2 with the lowest number of hospitalized COVID-19 patients in Madagascar (n = 7) and Brazil (n = 30). Our work provides new data about the bacterial community profile and the presence of pharmaceutical compounds in the hospital effluents from Brazil, Cameroon, and Madagascar, whose limited information is available. These compounds can exacerbate the spreading of antibiotic resistance and therefore pose a risk to public health., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. SARS-CoV-2 shedding, infectivity, and evolution in an immunocompromised adult patient.
- Author
-
Mendes-Correa MC, Ghilardi FR, Salomão MC, Villas-Boas LS, Paula AV, Paiao HGO, Costa ACD, Tozetto-Mendoza TR, Freire W, Sales FCS, Claro IM, Sabino EC, Faria NR, and Witkin SS
- Subjects
- Humans, Adult, Male, Lymphoma, Large B-Cell, Diffuse virology, Lymphoma, Large B-Cell, Diffuse immunology, Hematopoietic Stem Cell Transplantation, Whole Genome Sequencing, COVID-19 immunology, SARS-CoV-2 immunology, SARS-CoV-2 genetics, Immunocompromised Host, Virus Shedding
- Abstract
This study aimed to provide further insight into the evolutionary dynamics of SARS-CoV-2 by analyzing the case of a 40-year-old man who had previously undergone autologous hematopoietic stem cell transplantation due to a diffuse large B-cell lymphoma. He developed a persistent SARS-CoV-2 infection lasting at least 218 days and did not manifest a humoral immune response to the virus during this follow-up period. Whole-genome sequencing and viral cultures confirmed a persistent infection with a replication-positive virus that had undergone genetic variation for at least 196 days after symptom onset.
- Published
- 2024
- Full Text
- View/download PDF
22. Data-driven, cross-disciplinary collaboration: lessons learned at the largest academic health center in Latin America during the COVID-19 pandemic.
- Author
-
Ritto AP, de Araujo AL, de Carvalho CRR, De Souza HP, Favaretto PMES, Saboya VRB, Garcia ML, Kulikowski LD, Kallás EG, Pereira AJR, Cobello Junior V, Silva KR, Abdalla ERF, Segurado AAC, Sabino EC, Ribeiro Junior U, Francisco RPV, Miethke-Morais A, Levin ASS, Sawamura MVY, Ferreira JC, Silva CA, Mauad T, Gouveia NDC, Letaif LSH, Bego MA, Battistella LR, Duarte AJDS, Seelaender MCL, Marchini J, Forlenza OV, Rocha VG, Mendes-Correa MC, Costa SF, Cerri GG, Bonfá ESDO, Chammas R, de Barros Filho TEP, and Busatto Filho G
- Subjects
- Adult, Adolescent, Child, Humans, SARS-CoV-2, Pandemics, Latin America, COVID-19
- Abstract
Introduction: The COVID-19 pandemic has prompted global research efforts to reduce infection impact, highlighting the potential of cross-disciplinary collaboration to enhance research quality and efficiency., Methods: At the FMUSP-HC academic health system, we implemented innovative flow management routines for collecting, organizing and analyzing demographic data, COVID-related data and biological materials from over 4,500 patients with confirmed SARS-CoV-2 infection hospitalized from 2020 to 2022. This strategy was mainly planned in three areas: organizing a database with data from the hospitalizations; setting-up a multidisciplinary taskforce to conduct follow-up assessments after discharge; and organizing a biobank. Additionally, a COVID-19 curated collection was created within the institutional digital library of academic papers to map the research output., Results: Over the course of the experience, the possible benefits and challenges of this type of research support approach were identified and discussed, leading to a set of recommended strategies to enhance collaboration within the research institution. Demographic and clinical data from COVID-19 hospitalizations were compiled in a database including adults and a minority of children and adolescents with laboratory confirmed COVID-19, covering 2020-2022, with approximately 350 fields per patient. To date, this database has been used in 16 published studies. Additionally, we assessed 700 adults 6 to 11 months after hospitalization through comprehensive, multidisciplinary in-person evaluations; this database, comprising around 2000 fields per subject, was used in 15 publications. Furthermore, thousands of blood samples collected during the acute phase and follow-up assessments remain stored for future investigations. To date, more than 3,700 aliquots have been used in ongoing research investigating various aspects of COVID-19. Lastly, the mapping of the overall research output revealed that between 2020 and 2022 our academic system produced 1,394 scientific articles on COVID-19., Discussion: Research is a crucial component of an effective epidemic response, and the preparation process should include a well-defined plan for organizing and sharing resources. The initiatives described in the present paper were successful in our aim to foster large-scale research in our institution. Although a single model may not be appropriate for all contexts, cross-disciplinary collaboration and open data sharing should make health research systems more efficient to generate the best evidence., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Ritto, de Araujo, de Carvalho, De Souza, Favaretto, Saboya, Garcia, Kulikowski, Kallás, Pereira, Cobello Junior, Silva, Abdalla, Segurado, Sabino, Ribeiro Junior, Francisco, Miethke-Morais, Levin, Sawamura, Ferreira, Silva, Mauad, Gouveia, Letaif, Bego, Battistella, Duarte, Seelaender, Marchini, Forlenza, Rocha, Mendes-Correa, Costa, Cerri, Bonfá, Chammas, de Barros Filho and Busatto Filho.)
- Published
- 2024
- Full Text
- View/download PDF
23. Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation.
- Author
-
Diaz ACMB, Witkin SS, Almeida Neto C, Mendrone Junior A, Rocha V, Costa SF, Ramos JF, and Mendes-Correa MC
- Subjects
- Humans, Adult, Hepacivirus genetics, Retrospective Studies, Prevalence, Antiviral Agents therapeutic use, Brazil epidemiology, Liver Cirrhosis epidemiology, Hepatitis C complications, Hepatitis C epidemiology, Hematopoietic Stem Cell Transplantation adverse effects, Hepatitis C, Chronic drug therapy
- Abstract
Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation.
- Published
- 2024
- Full Text
- View/download PDF
24. Evaluation of enterovirus concentration, species identification, and cerebrospinal fluid parameters in patients of different ages with aseptic meningitis in São Paulo, Brazil.
- Author
-
Honorato L, Ferreira NE, Domingues RB, Senne C, Leite FBVM, Santos MVD, Fernandes GBP, Paião HGO, Vilas Boas LS, da Costa AC, Tozetto-Mendoza TR, Witkin SS, and Mendes-Correa MC
- Subjects
- Child, Adult, Adolescent, Humans, Infant, Brazil epidemiology, Retrospective Studies, Cerebrospinal Fluid, Enterovirus genetics, Meningitis, Aseptic cerebrospinal fluid, Meningitis, Viral, Enterovirus Infections
- Abstract
Human enteroviruses (EV) are the most common cause of aseptic meningitis worldwide. Data on EV viral load in cerebrospinal fluid (CSF) and related epidemiological studies are scarce in Brazil. This study investigated the influence of EV viral load on CSF parameters, as well as identifying the involved species. CSF samples were collected in 2018-2019 from 140 individuals at The Hospital das Clínicas, São Paulo. The EV viral load was determined using real-time quantitative polymerase chain reaction, while EV species were identified by 5'UTR region sequencing. Median viral load was 5.72 log
10 copies/mL and did not differ by subjects' age and EV species. Pleocytosis was observed in 94.3% of cases, with the highest white blood cell (WBC) counts in younger individuals. Viral load and WBC count were correlated in children (p = 0.0172). Elevated lactate levels were observed in 60% of cases and correlated with the viral load in preteen-teenagers (p = 0.0120) and adults (p = 0.0184). Most individuals had normal total protein levels (70.7%), with higher in preteen-teenagers and adults (p < 0.0001). By sequencing, 8.2% were identified as EV species A and 91.8% as species B. Age-specific variations in CSF characteristics suggest distinct inflammatory responses in each group., (© 2024 Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
25. Seroprevalence of hepatitis B, C, and D and associated factors in the semi-isolated Yanomami Amazonian indigenous community.
- Author
-
Vasconcelos MPA, Sánchez-Arcila JC, Peres L, de Sousa PSF, Castro-Alves J, Albuquerque HG, Mendes-Correa MC, Maia-Herzog M, Lewis-Ximenez LL, Villar LM, and Oliveira-Ferreira J
- Subjects
- Child, Humans, Adolescent, Hepatitis B Surface Antigens, Seroepidemiologic Studies, Cross-Sectional Studies, Hepatitis B Antibodies, Hepatitis B virus, Hepatitis C Antibodies, Prevalence, Hepatitis B epidemiology, Hepatitis B diagnosis, Hepatitis, Viral, Human epidemiology, Vaccines, Hepatitis C epidemiology
- Abstract
Background: Viral hepatitis is a significant health concern among indigenous population in the Americas. In Brazil, reports find high endemicity of HBV and HDV infections has been reported in several indigenous groups. However, few studies have documented the prevalence of HBV, HCV and HDV in the Yanomami. In this study, the prevalence of hepatitis B, C, and D serological markers and potential risk factors were investigated to provide guidance for the development of strategies aimed at reducing viral transmission in the Yanomami indigenous villages., Methods: This cross-sectional study was carried out in March 2015 and included 430 individuals from four Yanomami villages: Alapusi (n = 78), Castanha/Ahima (n = 126), Gasolina (n = 105), and Taibrapa (n = 121). A rapid test was used for detection of HBsAg and anti-HCV and chemiluminescent immunoassay for anti-HBs, anti-HBc, and anti-HDV antibodies., Results: HBsAg, anti-HBc, and anti-HBs were detected in 8.8, 45.5, and 49.4% of the participants, respectively. The estimated HBV status: current infection 9.6% (38/395); resolved infection 43.3% (171/395); vaccine immunity 20.5% (81/395), and susceptible to HBV 26.6% (105/395). Gasolina presented the lowest prevalence of HBV infection (6.5%) and the highest prevalence of vaccine immunity (26.9%). Children < 15 years old were highly susceptible to infection, as 53.1% did not have antibodies to HBV, while more than 80% of individuals over 45 years of age had been exposed to HBV. The markers for HDV were founded among 12.5% (4/32) of the HBsAg carriers. Anti-HCV was identified in all villages, with the highest prevalence in Alapusi (5.1%). Possible risk factors such as the use of piercings, tattoos, and contact with prospectors showed no statistical difference between the groups., Conclusions: Viral hepatitis B and serological markers for HCV and HDV were found to be widely distributed among the Yanomami indigenous community, while the prevalence of vaccine immunity to HBV was low. This finding reinforces the importance of promoting systematized diagnostic and vaccination strategies in indigenous communities. Our data confirm that isolated and difficult-to-reach indigenous communities lack appropriate access to diagnosis, treatment, and vaccination., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
26. Association between torquetenovirus in vaginal secretions and infertility: An exploratory metagenomic analysis.
- Author
-
Da Costa AC, Bortoletto P, Spandorfer SD, Tozetto-Mendoza TR, Linhares IM, Mendes-Correa MC, and Witkin SS
- Subjects
- Male, Humans, Female, Semen, Vagina, Infertility, Female, Torque teno virus genetics, Lactobacillus crispatus, Infertility, Male
- Abstract
Problem: The association of viruses with infertility remains incompletely evaluated., Method of Study: Vaginal secretions from 46 women seeking treatment in the Center for Reproductive Medicine and Infertility at Weill Cornell Medicine were tested for viruses by metagenomic analysis by lab personnel blinded to all clinical data., Results: Torquetenovirus (TTV) was identified in 16 women, alphapapillomavirus in seven women and most were positive for bacteriophages. Twelve of the subjects were fertile and sought to freeze their oocytes for future implantation. These women were all negative for TTV. In contrast, 16 of the 34 women (47.1%) being treated for infertility were TTV-positive (p = .0035). Evaluating the women by cause of infertility, five of nine women (55.6%) whose male partner had inadequate sperm parameters and six of 14 women (42.9%) with defective ovulation were TTV positive (p = .0062 and p = .0171, respectively, vs. the fertile women). Alphapapillomavirus was identified in one (8.3%) fertile woman, five (35.7%) women with ovulation deficiency, and one (11.1%) woman with male factor infertility. These differences were not statistically significant. There were no differences in bacteriophage families or the presence of Lactobacillus phages between fertile or infertile women or between different causes of infertility. There was a negative association between TTV detection and Lactobacillus crispatus dominance in the vaginal microbiota (p = .0184), but no association between TTV detection and the presence of alphapapillomavirus or Candida species., Conclusion: Detection of TTV in the vagina might be a biomarker for specific causes of infertility., (© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
27. Detailed characterization of Redondovirus in saliva of SARS-CoV-2-infected individuals in Sao Paulo, Brazil.
- Author
-
Charlys da Costa A, Mendes-Correa MC, Tozetto-Mendoza TR, Villas-Boas LS, de Paula AV, Paiao HGO, Leal FE, Ferreira NE, Honorato L, Leal E, Grandi G, Dos Santos Morais V, Manuli ER, Sabino EC, and Witkin SS
- Subjects
- Female, Male, Humans, Brazil epidemiology, Phylogeny, Saliva, SARS-CoV-2, COVID-19
- Abstract
Background: Redondovirus (ReDoV) is a DNA virus present in the respiratory tract of many healthy individuals. Since SARS-CoV-2, the virus responsible for COVID-19, also primarily infects the same site, we evaluated whether ReDoV was present at increased frequency in patients with COVID-19 and influenced infection parameters., Methods: Saliva samples were collected weekly from 59 individuals with COVID-19 and from 132 controls. ReDoV was detected by polymerase chain reaction and the genotypes were identified by metagenomics. Torque Teno Virus (TTV) in these samples were previously reported., Results: ReDoV was detected in saliva more frequently from COVID-19 patients (72.9%) than from controls (50.0%) (p = 0.0015). There were no associations between ReDoV detection and either continuous or intermittent SARS-CoV-2 shedding, the duration of SARS-CoV-2 detection in saliva, patients' sex or if infection was by the B1 or Gamma strain. The two ReDoV strains, Brisavirus and Vientovirus, were present in equivalent frequencies in ReDoV-positive COVID-19 patients and controls. Phylogenetic analysis suggested that the two ReDoV strains in Brazil were similar to strains previously detected on other continents., Conclusion: ReDoV expression in saliva is increased in males and females in Brazil with mild COVID-19 but its presence does not appear to influence properties of the SARS-CoV-2 infection., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Charlys da Costa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
28. Encephalopathy Caused by Human Parvovirus B19 Genotype 1 Associated with Haemophilus influenzae Meningitis in a Newborn.
- Author
-
Ferreira NE, da Costa AC, Kallas EG, Silveira CGT, de Oliveira ACS, Honorato L, Paião HGO, Lima SH, de M Vasconcelos D, Côrtes MF, Costa SF, Mendoza TRT, Gomes HR, Witkin SS, and Mendes-Correa MC
- Abstract
Parvovirus B19 infection is associated with a wide range of clinical manifestations, from asymptomatic to severe neurological disorders. Its major clinical symptoms, fever and rash, are common to multiple viruses, and laboratory tests to detect B19 are frequently not available. Thus, the impact of B19 on public health remains unclear. We report the case of a 38-day old girl admitted to São Paulo Clinical Hospital, Brazil, with an initial diagnosis of bacterial meningitis, seizures, and acute hydrocephalus. Antibiotic therapy was maintained for one week after admission and discontinued after negative laboratory results were obtained. Nine days after symptoms onset, a cerebral spinal fluid (CSF) sample revealed persistent pleocytosis. The complete B19 complete genome was subsequently identified in her CSF by a metagenomic next-generation sequencing approach. This report highlights the possible involvement of B19 in the occurrence of acute neurological manifestations and emphasizes that its possible involvement might be better revealed by the use of metagenomic technology to detect viral agents in clinical situations of unknown or uncertain etiology.
- Published
- 2023
- Full Text
- View/download PDF
29. Characterization of Torquetenovirus in amniotic fluid at the time of in utero fetal surgery: correlation with early premature delivery and respiratory distress.
- Author
-
Tozetto-Mendoza TR, da-Costa AC, Moron AF, Leal É, Lima SH, Ferreira NE, Honorato L, Paião HGO, Freire WS, Mendes-Correa MC, and Witkin SS
- Abstract
Torquetenovirus (TTV) is a commensal virus present in many healthy individuals. Although considered to be non-pathogenic, its presence and titer have been shown to be indicative of altered immune status in individuals with chronic infections or following allogeneic transplantations. We evaluated if TTV was present in amniotic fluid (AF) at the time of in utero surgery to correct a fetal neurological defect, and whether its detection was predictive of adverse post-surgical parameters. AF was collected from 27 women by needle aspiration prior to a uterine incision. TTV titer in the AF was measured by isolation of viral DNA followed by gene amplification and analysis. The TTV genomes were further characterized and sequenced by metagenomics. Pregnancy outcome parameters were subsequently obtained by chart review. Three of the AFs (11.1%) were positive for TTV at 3.36, 4.16, and 4.19 log
10 copies/mL. Analysis of their genomes revealed DNA sequences similar to previously identified TTV isolates. Mean gestational age at delivery was >2 weeks earlier (32.5 vs. 34.6 weeks) and the prevalence of respiratory distress was greater (100% vs. 20.8%) in the TTV-positive pregnancies. TTV detection in AF prior to intrauterine surgery may indicate elevated post-surgical risk for earlier delivery and newborn respiratory distress., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Tozetto-Mendoza, da- Costa, Moron, Leal, Lima, Ferreira, Honorato, Paião, Freire, Mendes-Correa and Witkin.)- Published
- 2023
- Full Text
- View/download PDF
30. Association between development of severe COVID-19 and a polymorphism in the CIAS1 gene that codes for an inflammasome component.
- Author
-
Tozetto-Mendoza TR, Mendes-Correa MC, Linhares IM, de Cássia Raymundi V, de Oliveira Paião HG, Barbosa EMG, Luna-Muschi A, Honorato L, Correa GF, da Costa AC, Costa SF, and Witkin SS
- Subjects
- Humans, Cytokines, Gene Frequency, Polymorphism, Genetic, COVID-19 genetics, Inflammasomes genetics, NLR Family, Pyrin Domain-Containing 3 Protein genetics
- Abstract
An elevated pro-inflammatory cytokine response is associated with severe life-threatening symptoms in individuals with Coronavirus Disease-2019 (COVID). The inflammasome is an intracellular structure responsible for generation of interleukin (IL)-1β and IL-18. NALP3, a product of the CIAS1 gene, is the rate-limiting component for inflammasome activity. We evaluated if a CIAS1 42 base pair length polymorphism (rs74163773) was associated with severe COVID. DNA from 93 individuals with severe COVID, 38 with mild COVID, and 98 controls were analyzed for this polymorphism. The 12 unit repeat allele is associated with the highest inflammasome activity. Five alleles, corresponding to 6, 7, 9, 12 or 13 repeat units, divided into 12 genotypes were identified. The frequency of the 12 unit repeat allele was 45.3% in those with severe disease as opposed to 30.0% in those with mild disease and 26.0% in controls (p < 0.0001, severe vs. controls). In contrast, the 7 unit repeat allele frequency was 30.1% in controls as opposed to 14.0% and 12.5% in those with severe or mild disease, respectively (p ≤ 0.0017). We conclude that individuals positive for the CIAS1 12 allele may be at elevated risk for development of severe COVID due to an increased level of induced pro-inflammatory cytokine production., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
31. SARS-CoV-2 Detection and Culture in Different Biological Specimens from Immunocompetent and Immunosuppressed COVID-19 Patients Infected with Two Different Viral Strains.
- Author
-
Mendes-Correa MC, Salomão MC, Ghilardi F, Tozetto-Mendoza TR, Santos Villas-Boas L, de Paula AV, Paiao HGO, da Costa AC, Leal FE, Ferraz ABC, Sales FCS, Claro IM, Ferreira NE, Pereira GM, da Silva AR Jr, Freire W, Espinoza EPS, Manuli ER, Romano CM, de Jesus JG, Sabino EC, and Witkin SS
- Subjects
- Humans, SARS-CoV-2 genetics, COVID-19 Testing, Specimen Handling, Virus Shedding, RNA, Viral genetics, COVID-19 diagnosis
- Abstract
Introduction-The dynamics of SARS-CoV-2 shedding and replication in humans remain incompletely understood. Methods-We analyzed SARS-CoV-2 shedding from multiple sites in individuals with an acute COVID-19 infection by weekly sampling for five weeks in 98 immunocompetent and 25 immunosuppressed individuals. Samples and culture supernatants were tested via RT-PCR for SARS-CoV-2 to determine viral clearance rates and in vitro replication. Results-A total of 2447 clinical specimens were evaluated, including 557 nasopharyngeal swabs, 527 saliva samples, 464 urine specimens, 437 anal swabs and 462 blood samples. The SARS-CoV-2 genome sequences at each site were classified as belonging to the B.1.128 (ancestral strain) or Gamma lineage. SARS-CoV-2 detection was highest in nasopharyngeal swabs regardless of the virus strain involved or the immune status of infected individuals. The duration of viral shedding varied between clinical specimens and individual patients. Prolonged shedding of potentially infectious virus varied from 10 days up to 191 days, and primarily occurred in immunosuppressed individuals. Virus was isolated in culture from 18 nasal swab or saliva samples collected 10 or more days after onset of disease. Conclusions-Our findings indicate that persistent SARS-CoV-2 shedding may occur in both competent or immunosuppressed individuals, at multiple clinical sites and in a minority of subjects is capable of in vitro replication.
- Published
- 2023
- Full Text
- View/download PDF
32. Factors Associated with Spontaneous Clearance of Recently Acquired Hepatitis C Virus among HIV-Positive Men in Brazil.
- Author
-
Ferrufino RQ, Rodrigues C, Figueiredo GM, Gleison D, Yapura S, de Matos MLM, Witkin SS, and Mendes-Correa MC
- Subjects
- Humans, Male, Female, Adult, Hepacivirus, Brazil epidemiology, Homosexuality, Male, Sexual and Gender Minorities, Hepatitis C complications, Hepatitis C epidemiology, HIV Seropositivity
- Abstract
Introduction: The objective of the present study was to describe the clinical and epidemiological aspects of recently acquired hepatitis C virus (HCV) infection and the frequency of its spontaneous clearance in a people living with the human immunodeficiency virus (PLWH) cohort., Methods: We reviewed the medical records from all PLWH at the human immunodeficiency virus (HIV) outpatient reference clinic affiliated with the University of São Paulo, Brazil, and identified, by immunoassays and RNA-PCR individuals who acquired HCV infection between January 2015 and December 2017. The factors associated with subsequent spontaneous clearance of the infection in this group were identified and analyzed., Results: Among 3143 PLWH individuals, 362 (11.5%) were coinfected with HCV. Forty-eight (13.2%) of these subjects first became HCV-positive between January 2015 and December 2017. Spontaneous HCV clearance was documented in 23 individuals (47.9%). The majority of this latter group were male (83.3%), and the median age was 31 years (23-39). The main risk group for HCV acquisition was men who had sex with men (MSM) (89.5%). In a multivariate analysis, only an elevated CD4+ T lymphocyte count at the time of seroconversion was found to be associated with subsequent HCV clearance ( p = 0.025)., Conclusions: In HIV-infected individuals in Sao Paulo, Brazil, most cases of recent HCV transmission were by sexual exposure. In PLWH, particularly in MSM, the individual's CD4+ T lymphocyte count is a determinant of whether an acquired HCV infection will be prolonged or will spontaneously clear.
- Published
- 2023
- Full Text
- View/download PDF
33. The Changing Epidemiology of Hepatitis C Virus Acquisition Among HIV-Infected Individuals in Brazil.
- Author
-
Ferrufino RQ, Bierrenbach AL, Rodrigues C, Figueiredo GM, Gleison D, Yapura S, de Matos MLM, Vasconcelos R, Sol Witkin S, and Mendes-Correa MC
- Subjects
- Humans, Hepacivirus genetics, Brazil epidemiology, Cross-Sectional Studies, Genotype, HIV Infections complications, HIV Infections epidemiology, Coinfection epidemiology, Hepatitis C complications, Hepatitis C epidemiology
- Abstract
Identification of mechanisms of hepatitis C virus (HCV) acquisition among HIV-infected people is critical for prevention guidance. The aim of this study was to investigate risk factors for HCV infection and variations in HCV genotype distribution in a cohort of HIV-HCV coinfected patients in Brazil. This was a cross-sectional observational epidemiological study of a cohort of HIV-HCV coinfected individuals seen at a referral center for HIV-infected patients in the city of São Paulo between January and December 2017. The time of HCV acquisition, as determined by chart review, was categorized as before 2000, between 2000 and 2009, and from 2010 onward. HCV genotypes were determined by gene amplification and analysis. Among 3,143 HIV-infected individuals analyzed, 362 (11.5%) were HCV-HIV coinfected. Overall, the reported modes of HCV acquisition were sexual exposure in 172 (47.5%), injection drug use (IDU) in 86 (23.8%), use of inhaled drugs in 67 (18.5%) and blood transfusion in 10 (2.8%) individuals. All individuals who acquired HCV after IDU became infected before 2010. HCV acquisition by sexual contact was reported by 26.4%, 65.9%, and 63.8% of patients before 2000, between 2000 and 2009, and from 2010, respectively. There was an increase ( p < .001) in the proportion of cases due to sexual transmission from the period before 2000 (26.4%) to between 2000 and 2009 (65.9%). There was no corresponding increase from 2000 and 2009 to after 2010 ( p = .751). HCV genotype 1 was most prevalent at all time periods. The genotype 3 frequency decreased over time (test for trend p < .001), whereas genotype 4, extremely uncommon before 2010, became the second most prevalent genotype from 2010 onward. In HIV-infected individuals in Sao Paulo, Brazil, sexual transmission has replaced IDU as the most frequent mode of HCV acquisition.
- Published
- 2023
- Full Text
- View/download PDF
34. Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Shedding and Predictors of Viral Culture Positivity on Vaccinated Healthcare Workers With Mild Coronavirus Disease 2019.
- Author
-
Luna-Muschi A, Noguera SV, Borges IC, De Paula AV, Côrtes MF, Larocca C, Mari JF, Guimarães LSP, Torres PM, Scaccia N, Villas-Boas LS, da Silva AR, Andrade PS, Teixeira JC, Escadafal C, de Oliveira VF, Tozetto-Mendoza TR, Mendes-Correa MC, Levin AS, Sabino EC, and Costa SF
- Subjects
- Humans, Prospective Studies, Health Personnel, SARS-CoV-2 genetics, COVID-19 diagnosis
- Abstract
In this prospective cohort of 30 vaccinated healthcare workers with mild Omicron variant infection, we evaluated viral culture, rapid antigen test (RAT), and real-time reverse-transcription polymerase chain reaction (RT-PCR) of respiratory samples at days 5, 7, 10, and 14. Viral culture was positive in 46% (11/24) and 20% (6/30) of samples at days 5 and 7, respectively. RAT and RT-PCR (Ct ≤35) showed 100% negative predictive value (NPV), with positive predictive values (PPVs) of 32% and 17%, respectively, for predicting viral culture positivity. A lower RT-PCR threshold (Ct ≤24) improved culture prediction (PPV = 39%; NPV = 100%). Vaccinated persons with mild Omicron infection are potentially transmissible up to day 7. RAT and RT-PCR might be useful tools for shortening the isolation period., Competing Interests: Potential conflicts of interest. All authors have declared no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
35. Understanding Sabiá virus infections (Brazilian mammarenavirus).
- Author
-
Nastri AC, Duarte-Neto AN, Casadio LVB, Souza WM, Claro IM, Manuli ER, Selegatto G, Salomão MC, Fialkovitz G, Taborda M, Almeida BL, Magri MC, Guedes AR, Perdigão Neto LV, Sataki FM, Guimarães T, Mendes-Correa MC, Tozetto-Mendoza TR, Fumagalli MJ, Ho YL, Maia da Silva CA, Coletti TM, Goes de Jesus J, Romano CM, Hill SC, Pybus O, Rebello Pinho JR, Ledesma FL, Casal YR, Kanamura CT, Tadeu de Araújo LJ, Ferreira CSDS, Guerra JM, Figueiredo LTM, Dolhnikoff M, Faria NR, Sabino EC, Alves VAF, and Levin AS
- Subjects
- Antibodies, Neutralizing, Brazil epidemiology, Humans, Arenaviruses, New World, Cross Infection, Yellow Fever
- Abstract
Background: Only two naturally occurring human Sabiá virus (SABV) infections have been reported, and those occurred over 20 years ago., Methods: We diagnosed two new cases of SABV infection using metagenomics in patients thought to have severe yellow fever and described new features of histopathological findings., Results: We characterized clinical manifestations, histopathology and analyzed possible nosocomial transmission. Patients presented with hepatitis, bleeding, neurological alterations and died. We traced twenty-nine hospital contacts and evaluated them clinically and by RT-PCR and neutralizing antibodies. Autopsies uncovered unique features on electron microscopy, such as hepatocyte "pinewood knot" lesions. Although previous reports with similar New-World arenavirus had nosocomial transmission, our data did not find any case in contact tracing., Conclusions: Although an apparent by rare, Brazilian mammarenavirus infection is an etiology for acute hemorrhagic fever syndrome. The two fatal cases had peculiar histopathological findings not previously described. The virological diagnosis was possible only by contemporary techniques such as metagenomic assays. We found no subsequent infections when we used serological and molecular tests to evaluate close contacts., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
36. Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster.
- Author
-
Silva ARD Jr, Villas-Boas LS, Paula AV, Tozetto-Mendoza TR, Honorato L, Witkin SS, and Mendes-Correa MC
- Subjects
- Antibodies, Viral, Humans, SARS-CoV-2, Vaccination, Vaccines, Synthetic, mRNA Vaccines, Antibodies, Neutralizing, COVID-19 prevention & control
- Published
- 2022
- Full Text
- View/download PDF
37. Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant.
- Author
-
Villas-Boas LS, Paula AV, Silva ARD Jr, Paiao HGO, Tozetto-Mendoza TR, Manuli ER, Leal FE, Ferraz ABC, Sabino EC, Bierrenbach AL, Witkin SS, and Mendes-Correa MC
- Subjects
- Antibodies, Viral, COVID-19 Vaccines, Humans, Immunization, Passive, Neutralization Tests, SARS-CoV-2, COVID-19 Serotherapy, Antibodies, Neutralizing, COVID-19 therapy
- Abstract
Objectives: The aim of the present study was to evaluate if neutralizing antibody responses induced by infection with the SARS-CoV-2 strain that was dominant at the beginning of the pandemic or by the Gamma variant was effective against the Omicron variant., Methods: Convalescent sera from 109 individuals, never exposed to a SARS-CoV-2 vaccine, who had mild or moderate symptoms not requiring hospitalization following either a documented SARS-CoV-2 ancestral strain infection or a Gamma variant infection, were assayed for in vitro neutralizing antibody activity against their original strains and the Omicron variant., Results: Following an infection with the ancestral strain, 56 (93.3%), 45 (77.6%) and 1 (1.7%) serum sample were positive for neutralizing antibodies against the ancestral, Gamma variant, and Omicron variant, respectively. After infection with the Gamma variant, 43 (87.8%) and 2 (4.1%) sera were positive for neutralizing antibodies against the Gamma and Omicron variants, respectively., Conclusions: Neutralizing antibodies generated following mild or moderate infection with the SARS-CoV-2 ancestral strain or the Gamma variant are not protective against the Omicron variant., Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest., (Copyright © 2022. Published by Elsevier España, S.L.U.)
- Published
- 2022
- Full Text
- View/download PDF
38. Does hepatitis E deserve more attention?
- Author
-
Weissmann L, Hernandes Granato CF, Witkin SS, and Mendes-Correa MC
- Subjects
- Humans, Hepatitis E epidemiology
- Abstract
Competing Interests: Conflicts of interest The authors declare no conflicts of interest.
- Published
- 2022
- Full Text
- View/download PDF
39. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
- Author
-
Silva ARD Jr, Villas-Boas LS, Tozetto-Mendoza TR, Honorato L, Paula A, Witkin SS, and Mendes-Correa MC
- Subjects
- Antibodies, Neutralizing, Antibodies, Viral, Brazil, COVID-19 Vaccines, Humans, Pandemics, Vaccination, COVID-19 prevention & control, SARS-CoV-2
- Abstract
Vaccination is a fundamental tool to prevent SARS-CoV-2 infection and to limit the COVID-19 pandemic. The emergence of SARS-CoV-2 variants with multiple mutations has raised serious concerns about the ability of neutralizing antibody responses elicited by prior vaccination to effectively combat these variants. The neutralizing capacity against the Gamma, Delta and Omicron variants of sera from individuals immunized with the CoronaVac vaccine remains incompletely determined. The present study evaluated 41 health care workers at the Faculdade de Medicina of the Universidade de Sao Paulo, in Sao Paulo, Brazil, naive to previous SARS- CoV-2 infection, who were vaccinated with two doses of the CoronaVac SARS-CoV-2 vaccine 28 days apart. Neutralizing antibody levels against the Gamma, Delta, and Omicron variants were measured at 32 and 186 days after the second vaccination. We also measured neutralizing antibodies against Omicron in 34 of these individuals following a subsequent booster immunization with the Pfizer vaccine. Quantification of neutralizing antibodies was performed using the Cytopathic Effect-based Virus Neutralization test. Neutralization antibody activity against the Gamma, Delta and Omicron variants was observed in 78.0%, 65.9% and 58.5% of serum samples, respectively, obtained at a mean of 32 days after the second immunization. This decreased to 17.1%, 24.4% and 2.4% of sera having activity against Delta, Gamma and Omicron, respectively, at 186 days post-vaccination. The median neutralizing antibody titers at 32 days were 1:40, 1:20 and 1:20 against Gamma, Delta and Omicron, respectively, and decreased to an undetectable median level against all variants at the later time. A booster immunization with the Pfizer vaccine elicited neutralizing antibodies against Omicron in 85% of subjects tested 60 days after vaccination. We conclude that two doses of the CoronaVac vaccine results in limited protection of short duration against the Gamma, Delta and Omicron SARS-CoV-2 variants. A booster dose with the Pfizer vaccine induced antibody neutralizing activity against Omicron in most patients which was measurable 60 days after the booster.
- Published
- 2022
- Full Text
- View/download PDF
40. Evaluation of the Utilization of FilmArray Meningitis/Encephalitis in Children With Suspected Central Nervous System Infection: A Retrospective Case Series.
- Author
-
Barros Domingues R, Mendes-Correa MC, Vilela de Moura Leite FB, Vega Dos Santos M, and Senne Soares CA
- Subjects
- Child, Humans, Multiplex Polymerase Chain Reaction, Retrospective Studies, Central Nervous System Infections diagnosis, Encephalitis diagnosis, Meningitis diagnosis, Meningitis, Bacterial
- Abstract
Background: The etiology of central nervous system infections is often difficult to establish. FilmArray meningitis/encephalitis (ME) panel is a multiplex polymerase chain reaction for rapid identification of 14 pathogens. The aim of this study was to evaluate potential real-life contributions of the use of this method in the pediatric population., Methods: We herein report the results obtained with FilmArray ME in a retrospective case series of 367 children with suspected central nervous system infection. We identified viral and bacterial agents by FilmArray, and we evaluated the potential diagnostic contributions of the use of the panel taking into account the cytological, biochemical, and microbiological results of the cerebrospinal fluid (CSF) analysis., Results: The FilmArray ME panel detected a viral infection in 186 cases (50.7%) and a bacterial infection in 12 cases (3.3%). Fifty-three cases (28.4%) of viral infection had at least 1 CSF finding that could be mistaken for bacterial meningitis. Enterovirus was identified in 2 cases with normal CSF findings. Among 12 bacterial infection cases, only 6 (50%) had a positive result with conventional microbiology analysis (Gram stain and culture). The CSF findings suggestive of bacterial meningitis were found in all 6 cases in which FilmArray was the only method to identify bacterial etiological agent., Conclusions: FilmArray ME panel identified an etiological agent in cases in which conventional CSF analysis failed, providing potential clinical contributions to the management of such cases., Competing Interests: Disclosure: The authors declare no conflict of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
41. Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: A prospective cohort study of vaccinated and unvaccinated healthcare workers.
- Author
-
Luna-Muschi A, Borges IC, de Faria E, Barboza AS, Maia FL, Leme MD, Guedes AR, Mendes-Correa MC, Kallas EG, Segurado AC, Duarte AJS, Lazari CS, Andrade PS, Sales FCS, Claro IM, Sabino EC, Levin AS, and Costa SF
- Subjects
- Health Personnel, Humans, Prospective Studies, COVID-19, SARS-CoV-2
- Abstract
Competing Interests: Declaration of Competing Interest None.
- Published
- 2022
- Full Text
- View/download PDF
42. The vaginal Torquetenovirus titer varies with vaginal microbiota composition in pregnant women.
- Author
-
Tozetto-Mendoza TR, Mendes-Correa MC, Moron AF, Forney LJ, Linhares IM, Ribeiro da Silva A Jr, Honorato L, and Witkin SS
- Subjects
- Adult, Female, Humans, Pregnancy, Pregnant Women, Vagina virology, Microbiota physiology, Torque teno virus isolation & purification, Vagina microbiology
- Abstract
Torquetenovirus (TTV) is a nonpathogenic endogenous virus whose abundance varies with the extent of immune system activation. We determined if the TTV titer in the vagina of pregnant women was associated with vaginal microbiota composition and levels of compounds in vaginal secretions. Vaginal TTV and microbiota composition in 494 second trimester pregnant women were identified by gene amplification and analysis. Vaginal matrix metalloproteinases (MMPs), tissue inhibitors of MMP (TIMP) and lactic acid isomers were measured by ELISA. Dominance was defined as the relative abundance of a specific bacterium or species at >50% of the total number of bacteria identified. Clinical data were obtained by chart review. The median log10 TTV titer was lowest when Lactobacillus species other than L. iners were dominant (<1.0) as compared to when L. iners (4.1, p = 0.0001), bacteria other than lactobacilli (4.5, p = 0.0016) or no bacterium (4.7, p = 0.0009) dominated. The TTV titer was inversely proportional to L. crispatus abundance (p<0.0001) and directly proportional to levels of G. vaginalis (p = 0.0008) and L. iners (p = 0.0010). The TTV titer was proportional to TIMP-1, TIMP-2, MMP-8 and MMP-9 abundance (p≤0.0002) and inversely proportional to the level of D-lactic acid (p = 0.0024). We conclude that the association between variations in the TTV titer and the relative abundance of specific bacterial species and vaginal compounds indicates that local changes in immune status likely influence vaginal fluid composition., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
43. The Torque Teno Virus Titer in Saliva Reflects the Level of Circulating CD4 + T Lymphocytes and HIV in Individuals Undergoing Antiretroviral Maintenance Therapy.
- Author
-
Honorato L, Witkin SS, Mendes-Correa MC, Conde Toscano ALC, Linhares IM, de Paula AV, Paião HGO, de Paula VS, Lopes AO, Lima SH, Raymundi VC, Ferreira NE, da Silva Junior AR, Abrahim KY, Braz-Silva PH, and Tozetto-Mendoza TR
- Abstract
Introduction: Torque teno virus (TTV) is a non-pathogenic virus present in body fluids. Its titer in the circulation increases in association with immune suppression, such as in HIV-infected individuals. We evaluated if the TTV titer in saliva from HIV-positive individuals undergoing antiretroviral therapy (ART) was related to the circulating CD4+ T lymphocyte concentration and the HIV titer., Methods: Saliva was collected from 276 asymptomatic individuals undergoing ART, and an additional 48 individuals positive for AIDS-associated Kaposi's Sarcoma (AIDS-KS). The salivary TTV titer was measured by gene amplification analysis. The circulating CD4+ T lymphocyte and HIV levels were obtained by chart review., Results: TTV was detectable in saliva from 80% of the asymptomatic subjects and 87% of those with AIDS-KS. In the asymptomatic group the median log
10 TTV titer/ml was 3.3 in 200 males vs. 2.4 in 76 females ( p < 0.0001). TTV titer/ml was 3.7 when HIV was acquired by intravenous drug usage, 3.2 when by sexual acquisition and 2.4 when blood transfusion acquired. The salivary TTV titer was inversely correlated with the circulating CD4+ T lymphocyte level ( p < 0.0001) and positively correlated with the circulating HIV concentration ( p = 0.0005). The median salivary TTV titer and circulating HIV titer were higher, and the CD4+ count was lower, in individuals positive for AIDS-KS than in the asymptomatic subjects ( p < 0.0001)., Conclusion: The TTV titer in saliva is a potential biomarker for monitoring immune status in individuals undergoing ART., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Honorato, Witkin, Mendes-Correa, Conde Toscano, Linhares, de Paula, Paião, de Paula, Lopes, Lima, Raymundi, Ferreira, da Silva Junior, Abrahim, Braz-Silva and Tozetto-Mendoza.)- Published
- 2022
- Full Text
- View/download PDF
44. An international, interlaboratory ring trial confirms the feasibility of an extraction-less "direct" RT-qPCR method for reliable detection of SARS-CoV-2 RNA in clinical samples.
- Author
-
Mills MG, Bruce E, Huang ML, Crothers JW, Hyrien O, Oura CAL, Blake L, Brown Jordan A, Hester S, Wehmas L, Mari B, Barby P, Lacoux C, Fassy J, Vial P, Vial C, Martinez JRW, Oladipo OO, Inuwa B, Shittu I, Meseko CA, Chammas R, Santos CF, Dionísio TJ, Garbieri TF, Parisi VA, Mendes-Correa MC, de Paula AV, Romano CM, Góes LGB, Minoprio P, Campos AC, Cunha MP, Vilela APP, Nyirenda T, Mkakosya RS, Muula AS, Dumm RE, Harris RM, Mitchell CA, Pettit S, Botten J, and Jerome KR
- Subjects
- COVID-19 virology, Feasibility Studies, Humans, Nasopharynx virology, Pandemics prevention & control, Sensitivity and Specificity, Serologic Tests methods, Specimen Handling methods, COVID-19 diagnosis, COVID-19 Testing methods, RNA, Viral genetics, Real-Time Polymerase Chain Reaction methods, Reverse Transcription genetics, SARS-CoV-2 genetics
- Abstract
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is used worldwide to test and trace the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). "Extraction-less" or "direct" real time-reverse transcription polymerase chain reaction (RT-PCR) is a transparent and accessible qualitative method for SARS-CoV-2 detection from nasopharyngeal or oral pharyngeal samples with the potential to generate actionable data more quickly, at a lower cost, and with fewer experimental resources than full RT-qPCR. This study engaged 10 global testing sites, including laboratories currently experiencing testing limitations due to reagent or equipment shortages, in an international interlaboratory ring trial. Participating laboratories were provided a common protocol, common reagents, aliquots of identical pooled clinical samples, and purified nucleic acids and used their existing in-house equipment. We observed 100% concordance across laboratories in the correct identification of all positive and negative samples, with highly similar cycle threshold values. The test also performed well when applied to locally collected patient nasopharyngeal samples, provided the viral transport media did not contain charcoal or guanidine, both of which appeared to potently inhibit the RT-PCR reaction. Our results suggest that direct RT-PCR assay methods can be clearly translated across sites utilizing readily available equipment and expertise and are thus a feasible option for more efficient COVID-19 coronavirus disease testing as demanded by the continuing pandemic., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
45. SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients.
- Author
-
Silva LTD, Ortega MM, Tiyo BT, Viana IFT, Lima TE, Tozetto-Mendoza TR, Oliveira LMDS, Teixeira FME, Lins RD, Almeida A, Mendes-Correa MC, Duarte AJDS, and Oshiro TM
- Subjects
- Antibodies, Viral, Humans, Immunity, Humoral, Recombinant Proteins, Spike Glycoprotein, Coronavirus, COVID-19, SARS-CoV-2
- Abstract
Objectives: In this preliminary study we investigated cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens in blood samples from 14 recovered coronavirus disease 2019 (COVID-19) patients and compared them to those in samples from 12 uninfected/unvaccinated volunteers., Methods: Cellular immunity was assessed by intracellular detection of IFN-γ in CD3+ T lymphocytes after stimulation with SARS-CoV-2 spike (S1), nucleocapsid (NC), or receptor-binding domain (RBD) recombinant proteins or overlapping peptide pools covering the sequence of SARS-CoV-2 spike, membrane and nucleocapsid regions. The humoral response was examined by ELISAs and/or chemiluminescence assays for the presence of serum IgG antibodies directed to SARS-CoV-2 proteins., Results: We observed differences between humoral and cellular immune profiles in response to stimulation with the same proteins. Assays of IgG antibodies directed to SARS-CoV-2 NC, RBD and S1/S2 recombinant proteins were able to differentiate convalescent from uninfected/unvaccinated groups. Cellular immune responses to SARS-CoV-2 protein stimuli did not exhibit a specific response, as T cells from both individuals with no history of contact with SARS-CoV-2 and from recovered donors were able to produce IFN-γ., Conclusions: Determination of the cellular immune response to stimulation with a pool of SARS-CoV-2 peptides but not with SARS-CoV-2 proteins is able to distinguish convalescent individuals from unexposed individuals. Regarding the humoral immune response, the screening for serum IgG antibodies directed to SARS-CoV-2 proteins has been shown to be specific for the response of recovered individuals.
- Published
- 2021
- Full Text
- View/download PDF
46. SARS-CoV-2 in a stream running through an underprivileged, underserved, urban settlement in São Paulo, Brazil: A 7-month follow-up.
- Author
-
Pepe Razzolini MT, Funada Barbosa MR, Silva de Araújo R, Freitas de Oliveira I, Mendes-Correa MC, Sabino EC, Garcia SC, de Paula AV, Villas-Boas LS, Costa SF, Dropa M, Brandão de Assis D, Levin BS, Pedroso de Lima AC, and Levin AS
- Subjects
- Brazil epidemiology, Follow-Up Studies, Humans, Pandemics, Urban Population, Vulnerable Populations, COVID-19 epidemiology, Rivers virology, SARS-CoV-2 isolation & purification
- Abstract
COVID-19 pandemic has led to concerns on the circulation of SARS-CoV-2 in the environment, its infectivity from the environment and, the relevance of transmission via environmental compartments. During 31 weeks, water samples were collected from a heavily contaminated stream going through an urban, underprivileged community without sewage collection. Our results showed a statistically significant correlation between cases of COVID-19 and SARS in the community, and SARS-CoV-2 concentrations in the water. Based on the model, if the concentrations of SARS-CoV-RNA (N1 and N2 target regions) increase 10 times, there is an expected increase of 104% [95%CI: (62-157%)] and 92% [95%CI: (51-143%)], respectively, in the number of cases of COVID-19 and SARS. We believe that differences in concentration of the virus in the environment reflect the epidemiological status in the community, which may be important information for surveillance and controlling dissemination in areas with vulnerable populations and poor sanitation. None of the samples were found infectious based cultures. Our results may be applicable globally as similar communities exist worldwide., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
47. Are mobile phones part of the chain of transmission of SARS-CoV-2 in hospital settings?
- Author
-
Espinoza EPS, Cortes MF, Noguera SV, Paula AV, Guimarães T, Boas LSV, Park M, Silva CCD, Morales I, Perdigão Neto LV, Tozetto-Mendoza TR, Boszczowski I, Sabino EC, Mendes-Correa MC, Levin AS, and Costa SF
- Subjects
- Animals, Chlorocebus aethiops, Cross-Sectional Studies, Hospitals, Humans, RNA, Viral, SARS-CoV-2, Vero Cells, COVID-19, Cell Phone
- Abstract
Mobile phones (MPs) have become an important work tool around the world including in hospitals. We evaluated whether SARS-CoV-2 can remain on the surface of MPs of first-line healthcare workers (HCW) and also the knowledge of HCWs about SARS-CoV-2 cross-transmission and conceptions on the virus survival on the MPs of HCWs. A cross-sectional study was conducted in the COVID-19 Intensive Care Unit of a teaching hospital. An educational campaign was carried out on cross-transmission of SARS-CoV-2, and its permanence in fomites, in addition to the proper use and disinfection of MPs. Herewith an electronic questionnaire was applied including queried conceptions about hand hygiene and care with MP before and after the pandemic. The MPs were swabbed with a nylon FLOQ Swab™, in an attempt to increase the recovery of SARS-CoV-2. All MP swab samples were subjected to SARS-CoV-2 RT-PCR; RT-PCR positive samples were subjected to viral culture in Vero cells (ATCC® CCL-81™). Fifty-one MPs were swabbed and a questionnaire on hand hygiene and the use and disinfection of MP was applied after an educational campaign. Most HCWs increased adherence to hand hygiene and MP disinfection during the pandemic. Fifty-one MP swabs were collected and two were positive by RT-PCR (4%), with Cycle threshold (Ct ) values of 34-36, however, the cultures of these samples were negative. Although most HCWs believed in the importance of cross-transmission and increased adherence to hand hygiene and disinfection of MP during the pandemic, SARS-CoV-2 RNA was detected in MPs. Our results suggest the need for a universal policy in infection control guidelines on how to care for electronic devices in hospital settings.
- Published
- 2021
- Full Text
- View/download PDF
48. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence and Risk Factors Among Oligo/Asymptomatic Healthcare Workers: Estimating the Impact of Community Transmission.
- Author
-
Costa SF, Giavina-Bianchi P, Buss L, Mesquita Peres CH, Rafael MM, Dos Santos LGN, Bedin AA, Francisco MCPB, Satakie FM, Jesus Menezes MA, Dal Secco LM, Rodrigues Caron DM, de Oliveira AB, de Faria MFL, de Aurélio Penteado AS, de Souza IOM, de Fatima Pereira G, Pereira R, Matos Porto AP, Sanchez Espinoza EP, Mendes-Correa MC, Dos Santos Lazari C, Kalil J, de Moliterno Perondi MB, de Oliveira Bonfa ESD, Perreira AJ, Sabino E, da Silva Duarte AJ, Segurado AC, Dos Santos VA, and Levin AS
- Subjects
- Cross-Sectional Studies, Health Personnel, Humans, Risk Factors, Seroepidemiologic Studies, COVID-19, SARS-CoV-2
- Abstract
We evaluated the seroprevalence of SARS-CoV-2 and risk factors among 4987 oligo/asymptomatic healthcare workers; seroprevalence was 14% and factors associated with SARS-CoV-2 infection were lower educational level (aOR, 1.93; 95% CI, 1.03-3.60), using public transport to work (aOR, 1.65; 95% CI, 1.07-2.62), and working in cleaning or security (aOR, 2.05; 95% CI, 1.04-4.03)., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
49. SARS-Cov-2 seroprevalence and risk factors among health care workers: Estimating the risk of COVID-19 dedicated units.
- Author
-
Oliveira MS, Lobo RD, Detta FP, Vieira-Junior JM, Castro TLS, Zambelli DB, Cardoso LF, Borges IC, Tozetto-Mendoza TR, Costa SF, and Mendes-Correa MC
- Subjects
- Health Personnel, Humans, Male, Risk Factors, Seroepidemiologic Studies, COVID-19, SARS-CoV-2
- Abstract
We evaluated the seroprevalence of SARS-CoV-2 and risk factors among 1,996 oligo/asymptomatic health care workers. The seroprevalence was 5.5% and risk factors associated with being infected with SARS-CoV-2 was professional category of cleaning (adj odds ratio 2.22, 95% confidence interval: 1.12-4.44, P: .023) and male gender (adj odds ratio: 1.54, 95% confidence interval: 1.03-2.32, P: .035).Working at dedicated COVID-19 units (high-risk group) was not an independent risk factor for seropositivity., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
50. Prolonged presence of replication-competent SARS-CoV-2 in mildly symptomatic individuals: A report of two cases.
- Author
-
Mendes Correa MC, Leal FE, Villas Boas LS, Witkin SS, de Paula A, Tozetto Mendonza TR, Ferreira NE, Curty G, de Carvalho PS, Buss LF, Costa SF, da Cunha Carvalho FM, Kawakami J, Taniwaki NN, Paiao H, da Silva Bizário JC, de Jesus JG, Sabino EC, Romano CM, Grepan RMZ, and Sesso A
- Subjects
- Animals, Chlorocebus aethiops, Female, Humans, Middle Aged, SARS-CoV-2 pathogenicity, Vero Cells ultrastructure, Vero Cells virology, Viral Load, Virus Shedding, COVID-19 immunology, COVID-19 virology, SARS-CoV-2 growth & development, Virus Cultivation
- Abstract
It has been estimated that individuals with COVID-19 can shed replication-competent virus up to a maximum of 20 days after initiation of symptoms. The majority of studies that addressed this situation involved hospitalized individuals and those with severe disease. Studies to address the possible presence of SARS-CoV-2 during the different phases of COVID-19 disease in mildly infected individuals, and utilization of viral culture techniques to identify replication-competent viruses, have been limited. This report describes two patients with mild forms of the disease who shed replication-competent virus for 24 and 37 days, respectively, after symptom onset., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.